Antibody formulations
By preparing a bispecific VEGF/ANG2 antibody liquid formulation containing specific concentrations and buffers, the stability and safety issues of high-concentration antibody formulations in the prior art have been solved. This has resulted in a low-viscosity, low-turbidity, and isotonic formulation suitable for intravitreal administration, avoiding the toxic effects of excipients.
Patent Information
- Application Number
- CN202411176182.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2018-10-29
- Filing Date
- 2019-10-25
- Publication Date
- 2024-11-29
AI Technical Summary
Existing technologies struggle to provide a stable, high-concentration, bispecific VEGF/ANG2 antibody liquid formulation suitable for intravitreal administration, while avoiding the use of excipients such as arginine, which may be toxic to the retina and retinal pigment epithelium.
By preparing a liquid formulation containing 20 mg/mL to 150 mg/mL of bispecific anti-VEGF/ANG2 antibody, 15 mM to 35 mM sodium chloride, 15 mM to 25 mM histidine acetate buffer, and a pH of 5.5 ± 0.5, and by adding stabilizers such as methionine and surfactant polysorbate 20, the formulation is ensured to have low viscosity, low turbidity, and isotonicity, while avoiding the use of potentially toxic excipients.
This achieved antibody stability and adaptability at high concentrations, ensuring the safety and efficacy of the formulation when administered intravitreal, and avoiding toxic effects on the retina and retinal pigment epithelium.
Smart Images

Figure CN119033684A_ABST
Abstract
Description
[0001] This application is a divisional application of the invention patent application with application date of October 25, 2019, application number 201980071143.2, and invention name “Antibody Preparation”. Technical Field
[0002] The present invention relates to a liquid pharmaceutical preparation of a bispecific antibody against angiopoietin-2 (ANG-2)-2 and human vascular endothelial growth factor (VEGF, VEGF-A) (bispecific anti-VEGF / ANG2 antibody) and a method for preparing and using the preparation. Background Art
[0003] Bispecific antibodies against angiopoietin-2 (ANG-2)-2 and human vascular endothelial growth factor (VEGF, VEGF-A) (bispecific anti-VEGF / ANG2 antibodies) are of therapeutic interest, in particular as drugs for the treatment and prophylactic treatment of vascular diseases (ocular vascular diseases). Bispecific anti-VEGF / ANG2 antibodies are described, for example, in WO2010040508, WO2011 / 117329 or WO2014 / 009465. These antibodies inhibit the binding of Vegf to VEGF receptors while allowing ANG-2 to bind to Tie2.
[0004] As part of the protein drug group, antibody molecules are very susceptible to physical and chemical degradation. Chemical degradation includes any process involving modification of proteins by bond formation or cleavage to obtain new chemical entities. A variety of chemical reactions are known to affect proteins. These reactions may involve hydrolysis (including cleavage of peptide bonds) and deamidation, isomerization, oxidation and decomposition. Physical degradation refers to changes in higher-order structures and includes denaturation, surface adsorption, aggregation and precipitation. Protein stability is affected by the characteristics of the protein itself (e.g., amino acid sequence, glycosylation pattern) and external influencing factors (such as temperature, solvent pH, excipients, interface or shear rate). Therefore, determining the optimal formulation conditions is important for protecting proteins from degradation reactions during production, storage and administration. (Manning, MC et al. (1989), "Stability of protein pharmaceuticals", Pharm Res 6(11), 903-918; Zheng, JY, Janis, LJ (2005), "Influence of pH, buffer species, and storage temperature on physicochemical stability of a humanized monoclonal antibody LA298", Int. J. Pharmaceutics 308, 46-51). It is particularly difficult to obtain stable liquid formulations of therapeutic antibodies when the formulation should contain high concentrations of the antibody.
[0005] Therefore, the object of the present invention is to provide a liquid (especially high concentration) formulation of a bispecific VEGF / ANG2 antibody, which contains as few necessary excipients as possible, enables the desired dosing, and facilitates the intravitreal administration of the bispecific antibody to a patient through a fine needle. Summary of the invention
[0006] The present invention relates to a liquid pharmaceutical formulation of a bispecific anti-VEGF / ANG2 antibody and a method for preparing and using the formulation. In particular, the pharmaceutical formulation of the present invention is used for intravitreal administration to treat ophthalmic diseases (such as AMD and DME).
[0007] In one aspect, the present invention relates to a liquid pharmaceutical formulation comprising:
[0008] - 20 mg / mL to 150 mg / mL of a bispecific anti-VEGF / ANG2 antibody comprising a heavy chain constant region of the human IgG1 subclass
[0009] -15mM to 35mM sodium chloride
[0010] -15mM to 25mM histidine acetate buffer
[0011] Its pH value is 5.5±0.5;
[0012] The bispecific anti-VEGF / ANG2 antibody is bivalent and comprises a first antigen binding site that specifically binds to human VEGF and a second antigen binding site that specifically binds to human ANG-2, wherein
[0013] i) the first antigen-binding site that specifically binds to VEGF comprises a CDR3H region of SEQ ID NO: 1, a CDR2H region of SEQ ID NO: 2, and a CDR1H region of SEQ ID NO: 3 in the heavy chain variable domain, and a CDR3L region of SEQ ID NO: 4, a CDR2L region of SEQ ID NO: 5, and a CDR1L region of SEQ ID NO: 6 in the light chain variable domain; and
[0014] ii) said second antigen-binding site that specifically binds to ANG-2 comprises in the heavy chain variable domain a CDR3H region of SEQ ID NO: 9, a CDR2H region of SEQ ID NO: 10, and a CDR1H region of SEQ ID NO: 11, and in the light chain variable domain a CDR3L region of SEQ ID NO: 12, a CDR2L region of SEQ ID NO: 13, and a CDR1L region of SEQ ID NO: 14, and wherein
[0015] iii) the bispecific antibody comprises a heavy chain constant region of human IgG1 subclass, the heavy chain constant region comprising mutations I253A, H310A and H435A and mutations L234A,
[0016] L235A and P329G (numbering according to the Kabat EU index).
[0017] In one embodiment, the bispecific anti-VEGF / ANG2 antibody is bivalent and comprises the amino acid sequence of SEQ ID NO:17, the amino acid sequence of SEQ ID NO:18, the amino acid sequence of SEQ ID NO:19, and the amino acid sequence of SEQ ID NO:20.
[0018] In one embodiment, the bispecific anti-VEGF / ANG2 antibody is faricimab.
[0019] In one embodiment, the formulation further comprises
[0020] -1 mM to 20 mM of at least one stabilizer.
[0021] In one embodiment, the formulation further comprises
[0022] -7.0 mM ± 2.0 mM methionine.
[0023] In one embodiment, the formulation further comprises
[0024] - 0.01% (w / v) to 0.07% (w / v) surfactant.
[0025] In one embodiment, the formulation further comprises
[0026] -0.04% (w / v) ± 0.02% (w / v) polysorbate 20.
[0027] In one embodiment, the formulation further comprises
[0028] -50mM to 250mM tonicity agent.
[0029] In one embodiment, the formulation further comprises
[0030] -160 mM ± 24 mM sucrose.
[0031] In one embodiment, the formulation is substantially free of visible particles.
[0032] In one embodiment, the formulation is a stable formulation.
[0033] In one embodiment, the osmotic pressure of the formulation is 300 mOsm / kg ± 100 mOsm / kg.
[0034] In one embodiment, the formulation is for intravitreal administration.
[0035] In one aspect, the formulation is used to treat an ocular vascular disease.
[0036] In one embodiment, the ocular vascular disease is selected from the group consisting of diabetic retinopathy (DR), diabetic macular edema (DME), retinal vein occlusion (RVO), central retinal vein occlusion (CRVO), macular degeneration, wet age-related macular degeneration (wet AMD), retinopathy of prematurity (ROP), neovascular glaucoma, retinitis pigmentosa (RP), retinal angiomatous proliferation, macular telangiectasia, ischemic retinopathy, iris neovascularization, intraocular neovascularization, corneal neovascularization, retinal neovascularization, choroidal neovascularization and retinal degeneration, specifically selected from the group consisting of diabetic retinopathy (DR), diabetic macular edema (DME), retinal vein occlusion (RVO), central retinal vein occlusion (CRVO), wet age-related macular degeneration (wet AMD).
[0037] One aspect of the present invention provides a method for preparing the pharmaceutical formulation according to the present invention.
[0038] One aspect of the present invention provides a vial comprising a pharmaceutical formulation according to the present invention.
[0039] One aspect of the present invention provides a prefilled syringe comprising a pharmaceutical formulation according to the present invention.
[0040] One aspect of the present invention provides a lyophilized liquid pharmaceutical formulation according to the present invention.
[0041] The present invention provides a liquid pharmaceutical formulation of a bispecific anti-VEGF / ANG2 antibody (comprising an IgG1 constant region) having valuable properties for ophthalmic use and intravitreal application: the formulation has low viscosity and low turbidity (even at high concentrations of about 120 mg / L), the formulation is stable and isotonic. This is achieved in particular by combining 20 mg / mL to 150 mg / mL (particularly 100 mg / mL to 140 mg / mL) of a bispecific anti-VEGF / ANG2 antibody comprising a heavy chain constant region of the human IgG1 subclass as described herein with 15 mM to 35 mM sodium chloride and 15 mM to 25 mM histidine buffer (pH 5.5±0.5). BRIEF DESCRIPTION OF THE DRAWINGS
[0042] Figure 1 Turbidity of formulations obtained from pH / buffer screening part I ( Figure 1A ) and viscosity ( Figure 1B 1 compares the turbidity and viscosity results of the formulations obtained from pH / buffer screening I (below the bars: first row: formulation sample number; second row: pH value; third row: buffer system; fourth row: ionic strength).
[0043] Figure 2 Turbidity of formulations obtained from pH / buffer screening part II ( Figure 2A ) and viscosity ( Figure 2B ) results (below the bars: first row: formulation sample number; second row: pH value; third row: absence of viscosity reducer-, presence of NaCl or CaCl2; fourth row: ionic strength).
[0044] Figure 3 High molecular weight species (HMW) of formulations obtained from pH / buffer screening part II, initially and after storage for 8 weeks at 5°C and 25°C (below the bars: first row: formulation sample number; second row: pH value; third row: in the absence of viscosity reducer-, in the presence of NaCl or CaCl2; fourth row: ionic strength).
[0045] Figure 4 Content of high molecular weight species (HMW) in the initial state and after physical stress (below the bars: first row: type of physical stress; second row: % surfactant; third row: formulation sample number).
[0046] FIG5 Turbidity of formulations obtained from excipient screening I ( Figure 5A ) and viscosity ( Figure 5B ) (Below the bars: first row: pH values in the absence (-) of NaCl as viscosity reducer or in the presence (+) of methionine as stabilizer; second row: formulation sample number).
[0047] Figure 6 Content of high molecular weight substances (HMW) in the initial state and during storage at 5°C (below the bars: first row: pH values in the absence (-) of NaCl as viscosity reducer or in the presence (+) of methionine as stabilizer; second row: formulation sample number).
[0048] Figure 7 Content of high molecular weight substances (HMW) in the initial state and during storage at 25°C (below the bars: first row: pH values in the absence (-) of NaCl as viscosity reducer or in the presence (+) of methionine as stabilizer; second row: formulation sample number).
[0049] Figure 8 Content of charged species (main peak ( Fig. 8A )、Acidic peak( Figure 8B ) and basic peak ( Figure 8C )) (below the bars: first row: pH values in the absence (-) of NaCl as viscosity reducer or in the presence (+) of methionine as stabilizer; second row: formulation sample number).
[0050] Figure 9 Content of charged species (main peak ( Fig.9A )、Acidic peak( Fig. 9B ) and basic peak ( Fig. 9C )) (below the bars: first row: pH values in the absence (-) of NaCl as viscosity reducer or in the presence (+) of methionine as stabilizer; second row: formulation sample number).
[0051] FIG. 10 shows the turbidity of the optimized formulation and the reference formulation with a protein concentration of 120 mg / mL obtained from excipient screening II ( Fig. 10A ) and viscosity ( Fig. 10B ).
[0052] FIG. 11 shows the turbidity of the optimized formulation and the reference formulation with a protein concentration of 30 mg / mL obtained from excipient screening II ( Fig.11A ) and viscosity ( Fig. 11B ).
[0053] Fig.12 Content of high molecular weight species (HMW) of the optimized formulation and the reference formulation at a protein concentration of 120 mg / mL at initial state (left bar) and after storage for 13 weeks at 5°C (middle bar) and 25°C (right bar).
[0054] Fig.13 Content of high molecular weight species (HMW) of the optimized formulation and the reference formulation at a protein concentration of 30 mg / mL at initial state (left bar) and after storage for 13 weeks at 5°C (middle bar) and 25°C (right bar).
[0055] Figure 14 The content of charged substances (main peak ( Fig.14A )、Acidic peak( Fig. 14B ) and basic peak ( Fig. 14C )). DETAILED DESCRIPTION
[0056] The present invention relates to a liquid pharmaceutical formulation comprising a bispecific anti-VEGF / ANG2 comprising a heavy chain constant region of human IgG1 subclass.
[0057] The term "pharmaceutical formulation" refers to a preparation that is in a form that permits the biological activity of the active ingredient to be clearly effective, and contains no additional components that would be toxic to a subject to which the formulation would be administered.
[0058] The term "liquid" as used herein in connection with the formulations according to the present invention refers to a formulation that is liquid at atmospheric pressure and at a temperature of at least about 2°C to about 35°C (in one embodiment, between about 2°C and about 25°C).
[0059] The concentration of the bispecific anti-VEGF / ANG2 antibody contained in the pharmaceutical formulation is in the range of about 20 mg / mL to about 150 mg / mL, particularly at a concentration of 120 mg / mL±18 mg / mL, more particularly at a concentration of 120 mg / mL±12 mg / mL. In another embodiment, the concentration may be 30 mg / mL±4.5 mg / mL.
[0060] As used herein, "antibody" refers to a binding protein that contains an antigen binding site. As used herein, the term "binding site" or "antigen binding site" refers to one or more regions of an antibody molecule to which a ligand actually binds. The term "antigen binding site" comprises an antibody heavy chain variable domain (VH) and an antibody light chain variable domain (VL) (VH / VL pair).
[0061] Antibodies specifically refer to the selective recognition of a specific epitope of an antigen by an antibody. For example, natural antibodies are monospecific.
[0062] According to the present invention, a "bispecific antibody" is an antibody with two different antigen binding specificities. The antibody of the present invention has specificity for two different antigens, wherein VEGF is the first antigen and ANG-2 is the second antigen.
[0063] As used herein, the term "monospecific" antibody refers to an antibody that has one or more binding sites that each bind to the same epitope of the same antigen.
[0064] The term "valency" as used in this application indicates the presence of a specified number of binding sites in an antibody molecule. Thus, the terms "bivalent", "tetravalent" and "hexavalent" indicate the presence of two binding sites, four binding sites and six binding sites in an antibody molecule, respectively. The bispecific antibody according to the present invention is preferably "bivalent".
[0065] As used herein, the terms "bispecific antibody that binds to human vascular endothelial growth factor (VEGF) and human angiopoietin-2 (ANG-2), "bispecific anti-VEGF / ANG2 antibody" and "bispecific <vegf ang2>"Antibody" are used interchangeably and refer to an antibody that has at least two different antigen binding sites, a first antigen binding site that binds to VEGF and a second antigen binding site that binds to ANG2.
[0066] Bispecific anti-VEGF / ANG2 antibodies are described, for example, in WO2010 / 040508, WO2011 / 117329, WO2012 / 131078, WO2015 / 083978, WO2017 / 197199, and WO2014 / 009465. WO2014 / 009465 describes bispecific anti-VEGF / ANG2 antibodies specifically designed for the treatment of ocular vascular diseases. The bispecific anti-VEGF / ANG2 antibodies of WO2014 / 009465 (which is incorporated herein by reference in its entirety) are particularly useful for the treatment of ocular vascular diseases and treatment regimens thereof as described herein. In particular, the anti-VEGF / ANG2 antibody CrossMAb VEGFang2-0016 as described in WO2014 / 009465 is also known as faricimab (in World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 118" WHO Drug Information. 31 (4)), which is a preferred bispecific anti-VEGF / ANG2 antibody of the present invention.
[0067] In one embodiment, the bispecific antibody that binds to human vascular endothelial growth factor (VEGF) and human angiopoietin-2 (ANG-2) is a bispecific anti-VEGF / ANG2 antibody comprising a first antigen binding site that specifically binds to human VEGF and a second antigen binding site that specifically binds to human ANG-2, wherein
[0068] i) the first antigen-binding site that specifically binds to VEGF comprises a CDR3H region of SEQ ID NO: 1, a CDR2H region of SEQ ID NO: 2, and a CDR1H region of SEQ ID NO: 3 in the heavy chain variable domain, and a CDR3L region of SEQ ID NO: 4, a CDR2L region of SEQ ID NO: 5, and a CDR1L region of SEQ ID NO: 6 in the light chain variable domain; and
[0069] ii) said second antigen-binding site that specifically binds to ANG-2 comprises in the heavy chain variable domain a CDR3H region of SEQ ID NO: 9, a CDR2H region of SEQ ID NO: 10, and a CDR1H region of SEQ ID NO: 11, and in the light chain variable domain a CDR3L region of SEQ ID NO: 12, a CDR2L region of SEQ ID NO: 13, and a CDR1L region of SEQ ID NO: 14, and wherein
[0070] iii) The bispecific antibody comprises a heavy chain constant region of human IgG1 subclass comprising the mutations I253A, H310A and H435A and the mutations L234A, L235A and P329G (numbering according to the Kabat EU index).
[0071] In one embodiment, such bispecific anti-VEGF / ANG2 antibodies are bivalent.
[0072] In one embodiment, such bispecific, bivalent anti-VEGF / ANG2 antibody is characterized by:
[0073] i) the first antigen binding site that specifically binds to VEGF comprises the amino acid sequence of SEQ ID NO: 7 as the heavy chain variable domain VH and the amino acid sequence of SEQ ID NO: 8 as the light chain variable domain VL, and
[0074] ii) the second antigen-binding site that specifically binds to ANG-2 comprises the amino acid sequence of SEQ ID NO: 15 as the heavy chain variable domain VH and the amino acid sequence of SEQ ID NO: 16 as the light chain variable domain VL.
[0075] In one aspect of the invention, such bispecific bivalent antibody according to the invention is characterized in that it comprises:
[0076] a) a heavy chain and a light chain of a first full-length antibody that specifically binds to VEGF;
[0077] b) A modified heavy chain and a modified light chain of a second full length antibody specifically binding to ANG-2, wherein the constant domains CL and CH1 are replaced with each other.
[0078] This bispecific, bivalent antibody format of a bispecific antibody specifically binding to human vascular endothelial growth factor (VEGF) and human angiopoietin-2 (ANG-2) is described in WO 2009 / 080253 (comprising a CH3 domain modified with a knob-in-hole structure). Antibodies based on this bispecific, bivalent antibody format are called CrossMAbs.
[0079] In one embodiment, such bispecific, bivalent anti-VEGF / ANG2 antibody is characterized in comprising:
[0080] a) a heavy chain of a first full-length antibody having the amino acid sequence of SEQ ID NO: 17, and
[0081] The light chain of the first full-length antibody has the amino acid sequence of SEQ ID NO: 18; and
[0082] b) a modified heavy chain of a second full length antibody having the amino acid sequence of SEQ ID NO: 19, and a modified light chain of a second full length antibody having the amino acid sequence of SEQ ID NO: 20.
[0083] In one embodiment, such bispecific, bivalent anti-VEGF / ANG2 antibody is characterized by comprising the amino acid sequence of SEQ ID NO:17, the amino acid sequence of SEQ ID NO:18, the amino acid sequence of SEQ ID NO:19, and the amino acid sequence of SEQ ID NO:20.
[0084] Therefore, one embodiment of the present invention is a bispecific, bivalent antibody comprising a first antigen binding site that specifically binds to human VEGF and a second antigen binding site that specifically binds to human ANG-2, the bispecific, bivalent antibody being characterized by comprising the amino acid sequence of SEQ ID NO: 17, the amino acid sequence of SEQ ID NO: 18, the amino acid sequence of SEQ ID NO: 19, and the amino acid sequence of SEQ ID NO: 20.
[0085] In one embodiment, the CH3 domain of the bispecific bivalent antibody according to the present invention is altered by the "knob-into-holes" technology, which is described in detail with several examples in, for example, WO 96 / 027011, Ridgway, JB et al., Protein Eng 9 (1996) 617-621 and Merchant, AM et al., Nat Biotechnol. 16 (1998) 677-681. In this method, the interaction surfaces of the two CH3 domains are altered to increase the heterodimerization of the two heavy chains comprising the two CH3 domains. One of the two CH3 domains (of the two heavy chains) can be a "knob" and the other a "hole". The introduction of disulfide bonds stabilizes the heterodimer (Merchant, AM et al., Nature Biotech 16 (1998) 677-681; Atwell, S. et al., J. Mol. Biol. 270 (1997) 26-35) and improves the yield.
[0086] In a preferred aspect of the present invention, the bispecific anti-VEGF / ANG2 antibody according to the present invention is characterized in that
[0087] The CH3 domain of one heavy chain meets the CH3 domain of the other heavy chain each at an interface that comprises the initial interface between antibody CH3 domains;
[0088] wherein the interface is altered to facilitate formation of a bispecific antibody, wherein the alteration is characterized by
[0089] In:
[0090] a) the CH3 domain of one heavy chain is altered,
[0091] so that within the initial interface where the CH3 domain of one heavy chain meets the initial interface of the CH3 domain of the other heavy chain within the bispecific antibody,
[0092] The amino acid residue is substituted with an amino acid residue having a larger side chain volume, thereby generating a protrusion within the interface of the CH3 domain of one heavy chain, which protrusion can be positioned in a cavity within the interface of the CH3 domain of the other heavy chain;
[0093] and
[0094] b) the CH3 domain of the other heavy chain is altered,
[0095] so that within the initial interface of the second CH3 domain that meets the initial interface of the first CH3 domain within the bispecific antibody,
[0096] The amino acid residues are substituted with amino acid residues having smaller side chain volumes, thereby generating a cavity within the interface of the second CH3 domain, which cavity can be positioned in the protrusion within the interface of the first CH3 domain.
[0097] Thus, the bispecific anti-VEGF / ANG2 antibodies as described herein are preferably characterized by a) the CH3 domain of the heavy chain of the full length antibody and b) the CH3 binding site of the heavy chain of the full length antibody.
[0098] The domains each comprise an altered interface of the original interface between antibody CH3 domains.
[0099] Meet at the place
[0100] wherein i) in the CH3 domain of a heavy chain
[0101] The amino acid residue is replaced with an amino acid residue having a larger side chain volume, thereby generating a protrusion within the interface of the CH3 domain of one heavy chain, which protrusion can be positioned in a cavity within the interface of the CH3 domain of the other heavy chain; and wherein
[0102] ii) in the CH3 domain of another heavy chain
[0103] The amino acid residue is replaced by an amino acid residue with a smaller side chain volume, thereby
[0104] A cavity is created within the interface of the domains, which cavity may be positioned in a protrusion within the interface of the first CH3 domain.
[0105] Preferably, the amino acid residue with a larger side chain volume is selected from the group consisting of arginine (R), phenylalanine (F), tyrosine (Y) and tryptophan (W).
[0106] Preferably, the amino acid residue with a smaller side chain volume is selected from the group consisting of alanine (A), serine (S), threonine (T) and valine (V).
[0107] In one aspect of the present invention, the two CH3 domains are further altered by introducing cysteine (C) as an amino acid at the corresponding position of each CH3 domain, so that a disulfide bond can be formed between the two CH3 domains.
[0108] In one embodiment, the bispecific antibody comprises a T366W mutation in the CH3 domain of the "knob chain" and a T366S, L368A, Y407V mutation in the CH3 domain of the "hole chain". Interchain disulfide bonds between CH3 domains can also be used (Merchant, AM et al., Nature Biotech 16 (1998) 677-681), for example by introducing an S354C mutation into one CH3 domain and a Y349C mutation into another CH3 domain.
[0109] In another preferred embodiment, the bispecific antibody comprises S354C and T366W mutations in one of the two CH3 domains and Y349C, T366S, L368A, Y407V mutations in the other of the two CH3 domains. In another preferred embodiment, the bispecific antibody comprises Y349C, T366W mutations in one of the two CH3 domains and S354C, T366S, L368A, Y407V mutations in the other of the two CH3 domains (the additional Y349C or S354C mutation in one CH3 domain and the additional S354C or Y349C mutation in the other CH3 domain form an interchain disulfide bond), wherein the mutations are numbered according to the Kabat EU index (Kabat, EA et al., Sequences of Proteins of Immunological Interest, 5th Edition, Public Health Service, National Institutes of Health, Bethesda, MD (1991)).
[0110] Other CH3 modification techniques for implementing heterodimerization are contemplated as alternatives to the present invention and are described, for example, in WO 96 / 27011, WO 98 / 050431, EP 1870459, WO 2007 / 110205, WO 2007 / 147901, WO 2009 / 089004, WO 2010 / 129304, WO 2011 / 90754, WO 2011 / 143545, WO 2012 / 058768, WO 2013 / 157954 and WO 2013 / 096291.
[0111] In one embodiment, the heterodimerization method described in EP 1 870 459A1 is used alternatively. The method is based on the substitution / mutation of charged amino acids with opposite charges introduced at specific amino acid positions at the CH3 / CH3 domain interface between the two heavy chains. A preferred embodiment of the multispecific antibody is the amino acid R409D and K370E mutations in the CH3 domain of one heavy chain of the multispecific antibody and the amino acid D399K and E357K mutations in the CH3 domain of another heavy chain (numbered according to the Kabat EU index).
[0112] In another embodiment, the multispecific antibody comprises an amino acid T366W mutation in the CH3 domain of the "knob chain" and amino acid T366S, L368A and Y407V mutations in the CH3 domain of the "hole chain"; and further comprises amino acid R409D and K370E mutations in the CH3 domain of the "knob chain" and amino acid D399K and E357K mutations in the CH3 domain of the "hole chain".
[0113] In one embodiment, the heterodimerization method described in WO2013 / 157953 is used instead. In one embodiment, the CH3 domain of one heavy chain comprises an amino acid T366K mutation, and the CH3 domain of another heavy chain comprises an amino acid L351D mutation. In another embodiment, the CH3 domain of one heavy chain further comprises an amino acid L351K mutation. In another embodiment, the CH3 domain of another heavy chain further comprises an amino acid mutation selected from Y349E, Y349D and L368E (in one embodiment, L368E).
[0114] In one embodiment, the heterodimerization method described in WO2012 / 058768 is used instead. In one embodiment, the CH3 domain of one heavy chain comprises amino acid L351Y and Y407A mutations, and the CH3 domain of another heavy chain comprises amino acid T366A and K409F mutations. In another embodiment, the CH3 domain of another heavy chain further comprises amino acid mutations at positions T411, D399, S400, F405, N390 or K392. In one embodiment, the amino acid mutation is selected from the group consisting of:
[0115] a) T411N, T411R, T411Q, T411K, T411D, T411E and T411W,
[0116] b)D399R, D399W, D399Y and D399K,
[0117] c) S400E, S400D, S400R and S400K,
[0118] d)F405I, F405M, F405T, F405S, F405V and F405W,
[0119] e) N390R, N390K and N390D,
[0120] f) K392V, K392M, K392R, K392L, K392F and K392E.
[0121] In another embodiment, the CH3 domain of one heavy chain comprises amino acid L351Y and Y407A mutations, and the CH3 domain of the other heavy chain comprises amino acid T366V and K409F mutations. In another embodiment, the CH3 domain of one heavy chain comprises amino acid Y407A mutation, and the CH3 domain of the other heavy chain comprises amino acid T366A and K409F mutations. In another embodiment, the CH3 domain of the other heavy chain further comprises amino acid K392E, T411E, D399R and S400R mutations.
[0122] In one embodiment, the heterodimerization method described in WO2011 / 143545 is used instead.In one embodiment, the amino acid modification according to WO2011 / 143545 is introduced into the following position in the CH3 domain of the heavy chain, the position being selected from the group consisting of 368 and 409.
[0123] In one embodiment, the heterodimerization method described in WO2011 / 090762 is used alternatively, which also uses the above-mentioned knob-in-hole structure technology. In one embodiment, the CH3 domain of one heavy chain comprises the amino acid T366W mutation, and the CH3 domain of the other heavy chain comprises the amino acid Y407A mutation. In one embodiment, the CH3 domain of one heavy chain comprises the amino acid T366Y mutation, and the CH3 domain of the other heavy chain comprises the amino acid Y407T mutation.
[0124] In one embodiment, the multispecific antibody is of IgG2 isotype and alternatively the heterodimerization method described in WO2010 / 129304 is used.
[0125] In one embodiment, the heterodimerization method described in WO2009 / 089004 is used instead. In one embodiment, the CH3 domain of one heavy chain comprises an amino acid replacement of a negatively charged amino acid pair K392 or N392 (in one embodiment, comprising a glutamic acid (E) or aspartic acid (D) replacement; in another embodiment, comprising a K392D or N392D mutation), and the CH3 domain of the other heavy chain comprises an amino acid replacement of a positively charged amino acid pair D399, E356, D356 or E357 (in one embodiment, comprising a lysine (K) or arginine (R) replacement; in another embodiment, comprising a D399K, E356K, D356K or E357K replacement; and in another embodiment, comprising a D399K or E356K mutation). In another embodiment, the CH3 domain of a heavy chain further comprises an amino acid replacement of a negatively charged amino acid pair K409 or R409 (in one embodiment, comprising a glutamic acid (E) or aspartic acid (D) replacement; in another embodiment, comprising a K409D or R409D mutation). In another embodiment, the CH3 domain of a heavy chain further or alternatively comprises an amino acid replacement of a negatively charged amino acid pair K439 and / or K370 (in one embodiment, a glutamic acid (E) or aspartic acid (D) replacement).
[0126] In one embodiment, the heterodimerization method described in WO2007 / 147901 is used instead.In one embodiment, the CH3 domain of one heavy chain comprises amino acid K253E, D282K and K322D mutations, and the CH3 domain of the other heavy chain comprises amino acid D239K, E240K and K292D mutations.
[0127] In one embodiment, the heterodimerization method described in WO2007 / 110205 is used instead.
[0128] In a preferred embodiment, such bispecific anti-VEGF / ANG2 antibodies are bivalent.
[0129] In one embodiment, the bispecific bivalent antibody that binds to human vascular endothelial growth factor (VEGF) and human angiopoietin-2 (ANG-2) is a bispecific anti-VEGF / ANG2 antibody comprising a first antigen binding site that specifically binds to human VEGF and a second antigen binding site that specifically binds to human ANG-2, wherein
[0130] i) the first antigen-binding site that specifically binds to VEGF comprises a CDR3H region of SEQ ID NO: 1, a CDR2H region of SEQ ID NO: 2, and a CDR1H region of SEQ ID NO: 3 in the heavy chain variable domain, and a CDR3L region of SEQ ID NO: 4, a CDR2L region of SEQ ID NO: 5, and a CDR1L region of SEQ ID NO: 6 in the light chain variable domain; and
[0131] ii) said second antigen-binding site that specifically binds to ANG-2 comprises in the heavy chain variable domain a CDR3H region of SEQ ID NO: 9, a CDR2H region of SEQ ID NO: 10, and a CDR1H region of SEQ ID NO: 11, and in the light chain variable domain a CDR3L region of SEQ ID NO: 12, a CDR2L region of SEQ ID NO: 13, and a CDR1L region of SEQ ID NO: 14, and wherein
[0132] iii) the bispecific antibody comprises a heavy chain constant region of human IgG1 subclass comprising the mutations I253A, H310A and H435A and the mutations L234A, L235A and P329G (numbering according to the Kabat EU index); and wherein
[0133] iv) in the heavy chain constant region, the T366W mutation is contained in one CH3 domain, and
[0134] The T366S, L368A, Y407V mutations are contained in another CH3 domain (numbering according to the Kabat EU index).
[0135] In one embodiment, the bispecific bivalent antibody that binds to human vascular endothelial growth factor (VEGF) and human angiopoietin-2 (ANG-2) is a bispecific anti-VEGF / ANG2 antibody comprising a first antigen binding site that specifically binds to human VEGF and a second antigen binding site that specifically binds to human ANG-2, wherein
[0136] i) the first antigen-binding site that specifically binds to VEGF comprises a CDR3H region of SEQ ID NO: 1, a CDR2H region of SEQ ID NO: 2, and a CDR1H region of SEQ ID NO: 3 in the heavy chain variable domain, and a CDR3L region of SEQ ID NO: 4, a CDR2L region of SEQ ID NO: 5, and a CDR1L region of SEQ ID NO: 6 in the light chain variable domain; and
[0137] ii) said second antigen-binding site that specifically binds to ANG-2 comprises in the heavy chain variable domain a CDR3H region of SEQ ID NO: 9, a CDR2H region of SEQ ID NO: 10, and a CDR1H region of SEQ ID NO: 11, and in the light chain variable domain a CDR3L region of SEQ ID NO: 12, a CDR2L region of SEQ ID NO: 13, and a CDR1L region of SEQ ID NO: 14, and wherein
[0138] iii) the bispecific antibody comprises a heavy chain constant region of human IgG1 subclass comprising the mutations I253A, H310A and H435A and the mutations L234A, L235A and P329G (numbering according to the Kabat EU index); and wherein
[0139] iv) In the heavy chain constant region, the S354C and T366W mutations are contained in one CH3 domain, and the Y349C, T366S, L368A and Y407V mutations are contained in the other CH3 domain (numbering according to the Kabat EU index).
[0140] In one embodiment, such bispecific, bivalent anti-VEGF / ANG2 is characterized by comprising the amino acid sequence of SEQ ID NO: 17, the amino acid sequence of SEQ ID NO: 18, the amino acid sequence of SEQ ID NO: 19, and the amino acid sequence of SEQ ID NO:20.
[0141] Therefore, one embodiment of the present invention is a bispecific, bivalent antibody comprising a first antigen binding site that specifically binds to human VEGF and a second antigen binding site that specifically binds to human ANG-2, the bispecific, bivalent antibody being characterized by comprising the amino acid sequence of SEQ ID NO: 17, the amino acid sequence of SEQ ID NO: 18, the amino acid sequence of SEQ ID NO: 19, and the amino acid sequence of SEQ ID NO: 20.
[0142] In a preferred embodiment, such bispecific anti-VEGF / ANG2 antibody is fariximab.
[0143] As used herein, the term "VEGF" refers to human vascular endothelial growth factor (VEGF / VEGF-A), 165-amino acid human vascular endothelial cell growth factor (amino acids 27-191 of the precursor sequence of human VEGF165: SEQ ID NO: 25; amino acids 1-26 represent the signal peptide) and the related 121, 189 and 206 vascular endothelial cell growth factor isoforms as described in the following literature: Leung, DW et al., Science 246 (1989) 1306-9; Houck et al., Mol. Endocrin. 5 (1991) 1806-1814; Keck, PJ et al., Science 246 (1989) 1309-12; and Connolly, DT et al., J. Biol. Chem. 264 (1989) 20017-24; as well as naturally occurring allelic forms and processed forms of these growth factors. VEGF is involved in the regulation of normal and abnormal angiogenesis and neovascularization associated with tumors and intraocular diseases (Ferrara, N. et al., Endocr. Rev. 18 (1997) 4-25; Berkman, RA et al., J. Clin. Invest. 91 (1993) 153-159; Brown, LF et al., Human Pathol. 26 (1995) 86-91; Brown, LF et al., Cancer Res. 53 (1993) 4727-4735; Mattern, J. et al., Brit. J. Cancer. 73 (1996) 931-934; and Dvorak, HF et al., Am. J. Pathol. 146 (1995) 1029-1039). VEGF is a homodimeric glycoprotein that has been isolated from a variety of sources and includes a variety of isoforms. VEGF has a highly specific mitogenic activity for endothelial cells. VEGF antagonists / inhibitors inhibit the binding of VEGF to its receptor VEGFR. Known VEGF antagonists / inhibitors include bispecific anti-VEGF / ANG2 antibodies as described in WO2014 / 009465.
[0144] As used herein, the term "ANG-2" refers to human angiopoietin-2 (ANG-2) (alternatively abbreviated as ANGPT2 or ANG2) (SEQ ID NO: 24), which is described, for example, in the following literature: Maisonpierre, PC et al., Science 277 (1997) 55-60; and Cheung, AH et al., Genomics 48 (1998) 389-91. Angiopoietin-1 and angiopoietin-2 were found to be ligands for Ties, a family of tyrosine kinases selectively expressed in vascular endothelium (Yancopoulos, GD et al., Nature 407 (2000) 242-48). The angiopoietin family now includes four defined members. Angiopoietin-3 and angiopoietin-4 (Ang-3 and Ang-4) may represent different counterparts of the same locus in mice and humans (Kim, I. et al., FEBS Let, 443 (1999) 353-56; Kim, I. et al., J Biol Chem 274 (1999) 26523-28). ANG-1 and ANG-2 were originally identified as agonists and antagonists, respectively, in tissue culture experiments (for ANG-1, see: Davis, S. et al., Cell 87 (1996) 1161-69; for ANG-2, see: Maisonpierre, PC et al., Science 277 (1997) 55-60). All known angiopoietins bind primarily to their receptor TIE2, and both Ang-1 and Ang-2 bind to TIE2 with an affinity of 3 nM (Kd) (Maisonpierre, PC et al., Science 277 (1997) 55-60). ANG2 antagonists / inhibitors inhibit the binding of ANG2 to its receptor TIE2. Known ANG2 antagonists / inhibitors include bispecific anti-VEGF / ANG2 antibodies as described in WO2014 / 009465.
[0145] The antigen binding site of the bispecific antibodies of the present invention comprises six complementary determining regions (CDRs), which contribute to the affinity of the antigen binding site to varying degrees. There are three heavy chain variable domain CDRs (CDRH1, CDRH2, and CDRH3) and three light chain variable domain CDRs (CDRL1, CDRL2, and CDRL3). The extent of the CDRs and framework regions (FRs) are determined by comparison with a compiled database of amino acid sequences, in which those regions have been defined based on the variability between sequences.
[0146] The antibodies of the present invention comprise an immunoglobulin constant region derived from human immunoglobulin class IgG1.
[0147] As used herein, the terms "monoclonal antibody" or "monoclonal antibody composition" refer to a preparation of antibody molecules of a single amino acid composition.
[0148] The term "chimeric antibody" refers to an antibody comprising a variable region (i.e., binding region) from one source or species and at least a portion of a constant region derived from a different source or species, which is usually prepared by recombinant DNA technology. Chimeric antibodies comprising a murine variable region and a human constant region are of particular interest. Other forms of "chimeric antibodies" encompassed by the present invention are antibodies in which the constant region has been modified or altered relative to the original antibody to produce the desired properties described in accordance with the present invention, especially with respect to C1q binding and / or Fc receptor (FcR) binding. Such chimeric antibodies are also referred to as "class-switched antibodies". Chimeric antibodies are the product of expressed immunoglobulin genes, which comprise a DNA segment encoding an immunoglobulin variable region and a DNA segment encoding an immunoglobulin constant region. Methods for producing chimeric antibodies involve conventional recombinant DNA, and gene transfection techniques are well known in the art. See, for example, the following: Morrison, SL et al., Proc. Natl. Acad. Sci. USA 81 (1984) 6851-6855; US Pat. Nos. 5,202,238 and 5,204,244.
[0149] The term "humanized antibody" refers to an antibody in which the framework or "complementarity determining region" (CDR) has been modified to contain CDRs of an immunoglobulin with different specificity compared to the parent immunoglobulin. In a preferred embodiment, the mouse CDRs are transplanted into the framework region of a human antibody to prepare a "humanized antibody". See, for example, the following documents: Riechmann, L. et al., Nature 332 (1988) 323-327; and Neuberger, MS et al., Nature 314 (1985) 268-270. Particularly preferred CDRs correspond to those sequences representing the antigens that recognize the above-mentioned chimeric antibodies. Other forms of "humanized antibodies" encompassed by the present invention are antibodies in which the constant regions have been additionally modified or altered relative to the original antibodies to produce the properties according to the present invention, particularly with respect to C1q binding and / or Fc receptor (FcR) binding.
[0150] The term "human antibody" as used herein is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. Human antibodies are well known in the art (van Dijk, MA and van de Winkel, JG, Curr. Opin. Chem. Biol. 5 (2001) 368-374). Human antibodies can also be produced in transgenic animals (e.g., mice) that are capable of producing a complete library or specific portions of human antibodies after immunization without producing endogenous immunoglobulins. Transfection of the human germline immunoglobulin gene array in such germline mutant mice will result in the production of human antibodies upon antigen challenge (see, e.g., Jakobovits, A. et al., Proc. Natl. Acad. Sci. USA 90 (1993) 2551-2555; Jakobovits, A. et al., Nature 362 (1993) 255-258; Bruggemann, M. et al., Year Immunol. 7 (1993) 33-40). Human antibodies can also be produced in phage display libraries (Hoogenboom, HR and Winter, G., J. Mol. Biol. 227 (1992) 381-388; Marks, JD et al., J. Mol. Biol. 222 (1991) 581-597). Human monoclonal antibodies can also be prepared using the techniques of Cole et al. and Boerner et al. (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985); and Boerner, P. et al., J. Immunol. 147 (1991) 86-95). As already mentioned for chimeric antibodies and humanized antibodies according to the invention, the term "human antibody" as used herein also includes such antibodies which have been modified in the constant region to produce the properties according to the invention, in particular with respect to C1q binding and / or FcR binding, for example by the "class switching" technique, i.e. the Fc part is altered or mutated (e.g. from IgG1 to IgG4 and / or IgG1 / IgG4 mutation).
[0151] As used herein, the term "recombinant human antibody" is intended to include all human antibodies prepared, expressed, produced or isolated by recombinant means, such as antibodies isolated from host cells (such as NS0 or CHO cells) or from animals (e.g., mice) transfected with human immunoglobulin genes, or antibodies expressed using recombinant expression vectors transfected into host cells. Such recombinant human antibodies have variable and constant regions in rearranged form. The recombinant human antibodies according to the present invention undergo in vivo somatic hypermutation. Therefore, the amino acid sequences of the VH and VL regions of the recombinant antibodies are sequences that, although derived from and related to human germline VH and VL sequences, may not be present in human antibody germline repertoires in vivo under natural conditions.
[0152] As used herein, the term "variable region" (light chain (V L ) variable region, heavy chain (V H The variable region of an antibody (or "variable region") or "variable domain" refers to each of a pair of light chain domains and heavy chain domains that are directly involved in the binding of an antibody to an antigen. The variable light chain domain and heavy chain domain have the same general structure, and each domain comprises four framework (FR) regions, the sequences of which are widely retained and connected by three "hypervariable regions" (or complementary determining regions, CDRs). The framework region adopts a β-sheet conformation, and the CDRs can form loops connecting the β-sheet structures. The CDRs in each chain maintain their three-dimensional structure through the framework region, and together with the CDRs in the other chain form an antigen binding site. The heavy and light chain CDR3 regions of an antibody play a particularly important role in the binding specificity / affinity of the antibodies according to the present invention. As used herein, the term "antigen-binding portion of an antibody" refers to the amino acid residues in an antibody that are responsible for antigen binding. The antigen-binding portion of an antibody comprises amino acid residues from the "complementary determining regions" or "CDRs". The "framework" or "FR" regions are those variable domain regions other than the hypervariable region residues defined herein. Therefore, the light chain variable domain and the heavy chain variable domain of the antibody comprise the domains FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4 from N-terminal to C-terminal. In particular, the CDR3 of the heavy chain is the region that is most helpful for antigen binding and defines the antibody properties. The CDR region and the FR region are defined according to the standard of Kabat et al. (Sequences of Proteins of Immunological Interest, 5th edition, Public Health Service, National Institutes of Health, Bethesda, MD (1991)) and / or determined from those residues of "hypervariable loop".
[0153] The term "epitope" includes any polypeptide determinant that is capable of specific binding to an antibody. In certain embodiments, epitope determinants include chemically active surface groups of molecules such as amino acids, sugar side chains, phosphoryl or sulfonyl groups, and in certain embodiments, may have specific three-dimensional structural characteristics and / or specific charge characteristics. An epitope is a region of an antigen that binds to an antibody.
[0154] The term "full-length antibody" refers to an antibody consisting of two "full-length antibody heavy chains" and two "full-length antibody light chains". A "full-length antibody heavy chain" is a polypeptide consisting of an antibody heavy chain variable domain (VH), an antibody constant heavy chain domain 1 (CH1), an antibody hinge region (HR), an antibody heavy chain constant domain 2 (CH2), and an antibody heavy chain constant domain 3 (CH3) in the N-terminal to C-terminal direction, abbreviated as VH-CH1-HR-CH2-CH3; if it is an antibody of the IgE subtype, it is optionally composed of an antibody heavy chain constant domain 4 (CH4). Preferably, a "full-length antibody heavy chain" is a polypeptide consisting of VH, CH1, HR, CH2, and CH3 in the N-terminal to C-terminal direction. A "full-length antibody light chain" is a polypeptide consisting of an antibody light chain variable domain (VL) and an antibody light chain constant domain (CL) in the N-terminal to C-terminal direction, abbreviated as VL-CL. The antibody light chain constant domain (CL) can be κ or λ. The two full-length antibody chains are linked together by inter-polypeptide disulfide bonds between the CL domain and the CH1 domain and between the hinge regions of the full-length antibody heavy chains. Typical examples of full-length antibodies are natural antibodies, such as IgG (e.g., IgG1 and IgG2), IgM, IgA, IgD, and IgE. The full-length antibodies according to the present invention may be from a single species, such as humans, or they may be chimeric antibodies or humanized antibodies. The full-length antibodies according to the present invention generally comprise two antigen binding sites, each of which is formed by a pair of VH and VL, both of which specifically bind to the same antigen. The C-terminus of the heavy or light chain of the full-length antibody represents the last amino acid at the C-terminus of the heavy or light chain. The N-terminus of the heavy or light chain of the full-length antibody represents the last amino acid at the N-terminus of the heavy or light chain.
[0155] The term "constant region" or "constant domain" as used in this application represents the sum of the domains outside the variable region in an antibody. The constant region does not directly participate in the combination of the antibody and the antigen, but exhibits a variety of effector functions. According to the different amino acid sequences of the constant region of its heavy chain, antibodies can be divided into the following categories: IgA, IgD, IgE, IgG and IgM, and some of them can be further divided into subclasses, such as IgG1, IgG2, IgG3 and IgG4 and IgA1 and IgA2. The heavy chain constant region corresponding to different classes of antibodies is respectively referred to as α, δ, ε, γ and μ. The light chain constant region present in all five antibody classes is referred to as κ and λ.
[0156] As used in the present application, the term "constant region derived from human origin" refers to the constant heavy chain region and / or constant light chain kappa or lambda region of a human antibody of subclass IgG1, IgG2, IgG3 or IgG4. Such constant regions are well known in the prior art and are described, for example, by Kabat, EA (see, for example: Johnson, G. and Wu, TT, Nucleic Acids Res. 28 (2000) 214-218; Kabat, EA et al., Proc. Natl. Acad. Sci. USA 72 (1975) 2785-2788).
[0157] The term "heavy chain constant domain (or region)" as used herein defines the C-terminal region of an immunoglobulin heavy chain that comprises at least a portion of the heavy chain constant region.
[0158] The term includes the natural sequence of the heavy chain constant domain and the variant heavy chain constant domain. The variant heavy chain constant domain includes, for example, mutations in the constant domain, which are used to promote heterodimerization as described above for the knob-and-hole structure technology. Other mutations may also be included, such as L234A (Leu235Ala), L235A (Leu234Ala) and P329G (Pro329Gly), because the constant domain with such mutations has a reduced FcR binding effect (especially they are no longer combined with FcRγI, FcRγII and FcRγIII). It is particularly suitable for reducing potential side effects, such as thrombosis (Meyer, T. et al., J.Thromb.Haemost.7 (2009) 171-81). Furthermore, for example, the mutations I253A, H310A and H435A (numbering according to the Kabat EU index) may also be included in the constant domain, since constant domains with such mutations have reduced FcRn binding (one or more mutations) or abolished FcRn binding (all 3 mutations).
[0159] In one aspect, human IgG heavy chain constant region extends from alanine 118 (A118) (according to Kabat EU index numbering) to the carboxyl end of heavy chain. However, the antibody produced by the host cell can undergo one or more, particularly one or two amino acid post-translational cleavages from the C-terminal of the heavy chain. Therefore, the antibody produced by the host cell by expressing a specific nucleic acid molecule encoding a full-length heavy chain can include a full-length heavy chain, or the antibody can include a cleavage variant of a full-length heavy chain. This may be a situation where the last two C-terminal amino acids of the heavy chain are glycine (G446) and lysine (K447, according to EU index coding). Therefore, the C-terminal lysine (Lys447) or C-terminal glycine (Gly446) and lysine (Lys447) of the heavy chain constant domain may exist or may not exist. Unless otherwise indicated, the amino acid sequence of the heavy chain including the heavy chain constant domain is represented herein by C-terminal glycine-lysine dipeptide.
[0160] A "stable" formulation is one in which a protein (e.g., an antibody) substantially retains its physical and chemical stability and its biological activity upon storage; for example, when the pharmaceutical formulation is stored at 25° C. for 8 weeks, the high molecular weight substance (HMW) content of the bispecific antibody in the pharmaceutical formulation is less than 10% (in one embodiment, less than 5%; in one embodiment, less than 2.5%). In one embodiment, when the pharmaceutical formulation is stored at 25° C. for 52 weeks, the high molecular weight substance (HMW) content of the bispecific antibody in the pharmaceutical formulation is less than 10% (in one embodiment, less than 5%).
[0161] In one embodiment, a "stable liquid pharmaceutical formulation" is a liquid formulation in which no significant changes are observed after storage at refrigerated temperature (2-8°C) for at least 12 months (particularly 2 years, more particularly 3 years). The stability criteria are as follows: no more than 10% (particularly 5%) of the antibody monomers are degraded as measured by size exclusion chromatography (SEC-HPLC). In addition, by visual analysis, the solution is colorless or clear to slightly opalescent. The protein concentration of the formulation does not vary by more than + / -10%. No more than 10% (particularly 5%) aggregates are formed. Stability is measured by known methods in the art such as UV spectroscopy, size exclusion chromatography (SEC-HPLC), ion exchange chromatography (IE-HPLC), turbidimetry, and visual inspection.
[0162] Turbidity (unit: FTU (=Formazine Turbidity Unit))
[0163] The turbidity of the pharmaceutical preparation can be determined by a turbidimeter (e.g., according to European Pharmacopoeia 2.2.1 "Clarity and opacity of liquids" on a Hach 2100AN turbidimeter). A sample volume of about 2 mL of the sample solution is transferred to a glass cuvette with an inner diameter of 11 mm. The glass cuvette is placed in the turbidimeter and the turbidity is measured according to the calibration curve of the reference suspension (1 FTU, 3 FTU, 10 FTU, 20 FTU and 100 FTU).
[0164] Viscosity (in mPa)
[0165] The viscosity of the drug product sample can be measured by rheometer (e.g., using Anton Paar Physica MCR 301 rotational rheometer with a taper of 25 mm–0.5° and a shear rate of 1000 s -1 , temperature is 20℃).
[0166] Visible particles
[0167] Visually inspect the sample in the vial with the aid of a 2x magnifying glass on a corresponding test device (e.g. Seidenader test device V90-T). Adjust the illumination sources L1, L2 and L3 to setting 5. During the rotational movement, check the sample in the vial for the presence of particles. According to USP-NF <790> The requirement of USP-NF ("substantially free of visible particles") is that for intravitreal injections, the formation of visible particles is unacceptable. <790> The standard states that when inspecting parenteral drugs, the "substantially free" criterion can be achieved and the number of units observed to contain visible particles does not exceed a specified number. More specifically, for parenteral drugs that are subject to 100% inspection, the "substantially free" criterion is achieved when the batch meets the acceptable quality level (AQL) of 0.65% or less. In addition, if it is necessary to evaluate product that has been delivered to customers (for example, due to complaints or regulatory reasons), the company can sample and inspect 20 units. If no particles are observed in the sample, the batch is considered "substantially free" of visible particles.
[0168] Protein concentration (in mg / mL).
[0169] The protein concentration of the formulation sample was measured by ultraviolet (UV) light absorption on a Perkin Elmer UV / Vis photometer λ35. The formulation sample was diluted with 20 mM L-histidine-acetate buffer (pH 5.5) to a protein concentration of about 0.5 mg / mL and then placed in a 1 cm thick cuvette. The UV absorbance of the cuvette was measured at wavelengths of 280 nm and 320 nm.
[0170] The protein concentration was calculated from the UV absorbance measured at 280 nm and 320 nm (A280 and A320, respectively), the extinction coefficient (E) of 1.70 mL / (mg x cm), the thickness (d) of 1 cm, and the dilution factor (DF) corresponding to the actual dilution using the following formula:
[0171]
[0172] pH
[0173] The pH of the formulation samples was measured potentiometrically using a glass electrode.
[0174] Ionic Strength
[0175] The dimensionless ionic strength I of the preparation is calculated according to Formula 1:
[0176] Formula 1
[0177] In this expression, z is the charge of the ion I (positive for cations and negative for anions), b i is its weight molar concentration. b θ corresponds to 1 mol / kg and is necessary to make I dimensionless (Physical Chemistry, P. Atkins, J. dePaula, Oxford Press, 9th edition, page 194).
[0178] The molar concentration of the charged buffer species was calculated using the Henderson-Hasselbalch formula (Methods in Enzymology-Guide to Protein Purification, Vol. 182, MP Deutscher, Academic Press, Inc., 1990, p. 24ff).
[0179] Osmotic pressure
[0180] The osmotic pressure of the formulation samples was measured on an Osmomat 030 3P osmometer from Gonotec based on the freezing point depression principle.
[0181] Surfactants
[0182] The pharmaceutical formulations of the present invention contain surfactants to reduce aggregation and particle formation of antibodies. As used herein, the term "surfactant" refers to a pharmaceutical excipient used to protect protein formulations from mechanical stress (e.g., stirring and shearing). Examples of pharmaceutical surfactants include polyoxyethylene sorbitan fatty acid esters (Tweens), polyoxyethylene alkyl ethers (e.g., sold under the trade name Brij TM ) and polyoxyethylene-polyoxypropylene copolymers (Poloxamer, Pluronic).
[0183] Preferably, the surfactant is a polyoxyethylene sorbitan fatty acid ester or a poloxamer. An example of a polyoxyethylene sorbitan fatty acid ester is polysorbate 20 (available under the trade name Tween 20 TM Polysorbate 80 (sold under the trade name Tween 80 TM The preferred polyoxyethylene sorbitan fatty acid ester is polysorbate 20.
[0184] The above-mentioned surfactant is usually used in a concentration of 0.01% (w / v) or higher (e.g., 0.01% (w / v) to about 0.09% (w / v)). The surfactant in the pharmaceutical composition of the present invention is particularly used in a range of about 0.02% (w / v) to about 0.06% (w / v), more particularly in a range of about 0.03% (w / v) to about 0.05% (w / v), and even more particularly in a concentration of about 0.04% (w / v).
[0185] The term "poloxamers" as used herein include polyoxyethylene-polyoxypropylene triblock copolymers consisting of a central hydrophobic chain of polyoxypropylene flanked by two polyoxyethylene hydrophilic chains, known as poloxamer 188, consisting of, marketed by BASF (Parsippany, NJ) under the trade name PLURONIC Other poloxamers that can be used in the formulations of the present invention include poloxamer 403 (marketed as PLURONIC P123), Poloxamer 407 (sold as PLURONIC P127), Poloxamer 402 (sold as PLURONIC P122), Poloxamer 181 (sold as PLURONIC L61), Poloxamer 401 (sold as PLURONIC L121), Poloxamer 185 (sold as PLURONIC P65) and Poloxamer 338 (sold as PLURONIC F108 sales).
[0186] Buffer
[0187] The term "buffer" as used herein refers to a pharmaceutical excipient that is used to stabilize the pH of a pharmaceutical formulation. Suitable buffers are well known in the art and can be found in the literature. Typical pharmaceutical buffers for intravitreal administration include, but are not limited to, histidine buffers, citrate buffers, succinate buffers, acetate buffers, phosphate buffers, or mixtures thereof. In this context, buffers of particular interest include L-histidine ("histidine buffer") or a mixture of L-histidine and L-histidine hydrochloride, the pH of which is adjusted with an acid or base known in the art. Buffers of particular interest include L-histidine ("histidine buffer"), particularly L-histidine whose pH is adjusted by acetic acid (e.g., 30%) or hydrochloride. The above buffers are typically used in a concentration of about 2 mM to about 200 mM or about 5 mM to about 100 mM, particularly in a concentration of about 10 mM to about 30 mM or about 15 mM to about 20 mM, more particularly in a concentration of about 20 mM. Independently of the buffer used, the pH can be adjusted to a value in the range of 4.5 to 7.0, in particular to a value in the range of 5.0 to 6.0, and most particularly to pH 5.5 ± 0.2, with acids or bases known in the art (e.g. acetic acid, hydrochloric acid, phosphoric acid, sulfuric acid and citric acid, sodium hydroxide and potassium hydroxide, in particular acetic acid). A buffer of particular interest is histidine (L-histidine) at a concentration of 15-25 mM (in one embodiment 20 mM ± 3 mM, in particular 20 mM ± 2 mM) at a pH of 5.5 ± 0.5 (in one embodiment pH 5.5 ± 0.3; in particular pH 5.5 ± 0.2).
[0188] Stabilizer
[0189] The term "stabilizer" refers to a pharmaceutical excipient that is used to protect the active pharmaceutical ingredient and / or formulation from chemical and / or physical degradation during production, storage and use. The chemical and physical degradation pathways of protein drugs are reviewed in the following literature: Cleland et al. (1993), Crit Rev Ther Drug Carrier Syst 10(4):307-77; Wang (1999) Int J Pharm 185(2):129-88; Wang (2000) Int J Pharm 203(1-2):1-60; and Chi et al. (2003) Pharm Res 20(9):1325-36. Stabilizers include, but are not limited to, sugars, amino acids, polyols, cyclodextrins (e.g., hydroxypropyl-β-cyclodextrin, sulfobutylethyl-β-cyclodextrin, β-cyclodextrin), polyethylene glycols (e.g., PEG 3000, PEG3350, PEG 4000, PEG 6000), albumin, human serum albumin (HSA), bovine serum albumin (BSA), salts (e.g., sodium chloride, magnesium chloride, calcium chloride), chelating agents (e.g., EDTA as defined below). Stabilizers particularly used in the present invention are selected from the group consisting of sugars, polyols, and amino acids. More particularly, stabilizers are selected from the group consisting of sucrose, trehalose, sorbitol, and methionine.
[0190] More preferably, the stabilizer is methionine. The methionine used in the formulation described herein is for the first time for ocular administration. Preclinical safety trials have shown that methionine for the treatment of eye diseases exhibits good safety when administered, for example, intravitreally.
[0191] The stabilizer may be present in the formulation at a concentration of about 2 mM to about 600 mM, particularly if the stabilizer is methionine, it is present at a concentration of about 2 mM to about 15 mM or 5 mM to 12 mM; more particularly, at a concentration of about 5 mM to 9 mM or about 7 mM.
[0192] In a preferred embodiment, the stabilizer is methionine, and the methionine concentration is 7.0 mM ± 2.0 mM (in one embodiment, the methionine concentration is 7.0 mM ± 1.0 mM; in one embodiment, the methionine concentration is 7.0 mM ± 0.7 mM). Methionine is particularly useful as a stabilizer because it can also be used as a scavenger of hydrogen peroxide, where hydrogen peroxide is used to sterilize the injection solution or packaged prefilled syringes.
[0193] In certain embodiments, the liquid pharmaceutical formulation of the present invention comprises an antioxidant as a second stabilizer. "Antioxidant" is a pharmaceutical excipient that prevents oxidation of the active pharmaceutical ingredient. Antioxidants include, but are not limited to, chelating agents, such as EDTA, citric acid, ascorbic acid, butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), sodium sulfite, p-aminobenzoic acid, glutathione, propyl gallate, cysteine, methionine, ethanol, benzyl alcohol, and N-acetylcysteine. Antioxidants can be used at a concentration of about 0.01mM to about 100mM, particularly at a concentration of about 5mM to about 50mM, and more particularly at a concentration of about 5mM to about 25mM. In particular, methionine is selected as the second stabilizer, in particular, at a concentration of about 5mM to about 25mM, and more particularly at a concentration of about 10mM.
[0194] As used herein, the term "sugar" means monosaccharide or oligosaccharide. Monosaccharide is a monomeric carbohydrate that cannot be hydrolyzed by acid, including simple sugars and their derivatives (e.g., amino sugars). Examples of monosaccharides include glucose, fructose, galactose, mannose, sorbose, ribose, deoxyribose, neuraminic acid. Oligosaccharides are carbohydrates composed of more than one monomeric sugar unit, which are connected by one or more glycosidic bonds in a branch or chain. The monomeric sugar units in an oligosaccharide may be the same or different. Depending on the number of monomeric sugar units, oligosaccharides are disaccharides, trisaccharides, tetrasaccharides, pentasaccharides, etc. Compared with polysaccharides, monosaccharides and oligosaccharides are soluble in water. Examples of oligosaccharides include sucrose, trehalose, lactose, maltose, and raffinose. In particular, sugar is selected from sucrose and trehalose, in particular sucrose.
[0195] The term "amino acid" as used herein generally refers to a pharmaceutically acceptable organic molecule having an amino moiety located at the α-position to a carboxyl group. Examples of amino acids include arginine, glycine, ornithine, lysine, histidine, glutamic acid, aspartic acid, isoleucine, leucine, alanine, phenylalanine, tyrosine, tryptophan, methionine, serine, proline, and particularly methionine.
[0196] The term "polyol" as used herein refers to a pharmaceutical alcohol having more than one hydroxyl group. Suitable polyols include, but are not limited to, mannitol, sorbitol, glycerol (glycerol), dextran, arabitol, propylene glycol, polyethylene glycol, and combinations thereof. The polyol can be used in a concentration of 10 mM to about 500 mM, particularly in a concentration of about 10 mM to about 250 mM, and more particularly in a concentration of about 200 mM to about 250 mM.
[0197] The term "stabilizer" also includes lyoprotectants. The term "lyoprotectant" refers to a pharmaceutical excipient used to protect unstable active ingredients (e.g., proteins) from unstable conditions during freeze drying and subsequent storage and reconstitution. Lyoprotectants include, but are not limited to, a group consisting of sugars, polyols (such as sugar alcohols) and amino acids. In particular, lyoprotectants may be selected from a group consisting of the following items: sugars, such as sucrose, trehalose, lactose, glucose, mannose, maltose, galactose, fructose, sorbose, raffinose, neuraminic acid; amino sugars, such as glucosamine, galactosamine, N-methylglucosamine ("methylglucamine"); polyols, such as mannitol and sorbitol; and amino acids, such as methionine or glycine. Lyoprotectants are typically used at a concentration of about 10mM to about 600mM, particularly at a concentration of about 10mM to about 250mM, and more particularly at a concentration of about 100mM to about 250mM.
[0198] Tonicity Agents
[0199] The pharmaceutical preparation may also include a tonicity agent. As used herein, the term "tonicity agent" refers to a pharmaceutical tonicity agent for adjusting the tonicity of the preparation. The preparation may be a hypotonic, isotonic or hypertonic preparation. Isotonicity generally relates to the osmotic pressure relative to the solution, which is generally relative to the osmotic pressure of human serum. The preparation according to the present invention may be a hypotonic, isotonic or hypertonic preparation, preferably, the pharmaceutical preparation is an isotonic preparation. An isotonic preparation is a liquid or a liquid obtained by reconstituting a solid form (e.g., from a lyophilized form) and represents a solution with similar tonicity to some other solution such as a physiological saline solution and serum compared thereto. Suitable tonicity agents include, but are not limited to, sodium chloride, potassium chloride, glycerol, and any component selected from the group consisting of amino acids, sugars (particularly sucrose). In one embodiment of the invention, the preferred tonicity agent is sucrose. The tonicity agent is generally used at a concentration of about 5mM to about 1000mM, particularly about 30mM to about 500mM, more particularly about 120mM to about 200mM. The tonicity agent used in the isotonic formulation of the present invention is generally used in a concentration of about 50 mM to about 250 mM, in particular about 120 mM to about 200 mM. More particularly, the tonicity agent used in the isotonic formulation is used in a concentration of 130 mM to 190 mM, and even more particularly, in the case of using sucrose as a tonicity agent, a concentration of about 160 mM ± 24 mM is used. The tonicity agent and its concentration are selected so that the isotonic formulation has a target osmotic pressure of 300 mOsm / kg ± 100 mOsm / kg (in particular, a target osmotic pressure of 300 mOsm / kg ± 50 mOsm / kg).
[0200] Among stabilizers and tonicity agents, a group of compounds can play two roles at the same time, that is, they act as stabilizers and tonicity agents at the same time. Examples of such compounds can be found in the group consisting of sugars, amino acids, polyols, cyclodextrins, polyethylene glycols and salts. An example of a sugar that can act as a stabilizer and tonicity agent at the same time is sucrose and trehalose, especially sucrose.
[0201] Viscosity reducer
[0202] The pharmaceutical formulation may include a viscosity reducing agent. As used herein, the term "viscosity reducing agent" refers to a pharmaceutically acceptable ionic strength modifier used to reduce the viscosity of the formulation, which is very useful for high concentration formulations and for formulations that are intended to be administered intravitreally through a fine needle in the treatment of ocular diseases (enabling relatively rapid administration without the use of high pressure injection). Examples of typical viscosity reducing agents are, for example, calcium chloride or sodium chloride.
[0203] Adjuvant
[0204] Pharmaceutical preparations may also include adjuvants, such as preservatives, wetting agents, emulsifiers and dispersants. Can be sterilized and added with various antibacterial and antifungal agents (e.g. parabens, chlorobutanol, phenol, sorbic acid, etc.) to ensure that there is no microorganism. Preservatives are usually used in a concentration of about 0.001% (w / v) to about 2% (w / v). Preservatives include but are not limited to ethanol, benzyl alcohol, phenol, metacresol, parachlorometacresol, methylparaben or propylparaben, benzalkonium chloride.
[0205] The pharmaceutical preparation may also contain a small amount of the above-mentioned different agents, such as buffers, surfactants, stabilizers, ionic strength modifiers, the content of which does not substantially change the technical characteristics of the pharmaceutical preparation of the present invention, for example, a viscosity of 20 mPas or less (preferably 15 mPas or less), a turbidity of 30 FTU or less (preferably 25 FTU or less), an osmotic pressure of 300 mOsm / kg ± 50 mOsm / kg and substantially no visible particles.
[0206] use
[0207] The bispecific anti-VEGF / ANG2 antibody pharmaceutical formulation according to the present invention can be used to prevent or treat ocular vascular diseases. To this end, the pharmaceutical formulation of the bispecific anti-VEGF / ANG2 antibody for intravitreal administration is provided as a liquid isotonic formulation having a viscosity of 20 mPas or less (preferably 15 mPas or less), a turbidity of 30 FTU or less (preferably 25 FTU or less), an osmotic pressure of 300 mOsm / kg±50 mOsm / kg, and substantially no visible particles. To this end, the liquid isotonic pharmaceutical formulation of the bispecific anti-VEGF / ANG2 antibody can be provided in a glass vial, or in the form of a prefilled syringe, in particular in the form of a prefilled glass syringe.
[0208] For such formulations administered intravitreally to the eye, excipients such as arginine should be avoided because toxicity of arginine as a carrier of tissue plasminogen activator (t-PA) to the retina and retinal pigment epithelium has been reported (see, e.g., Benner JD, Morse LS, Toth CA, et al., Arch Ophthalmol 1991 109 1731-1736.1736; Johnson MW, Olsen KR, Hernandez E., et al., Arch Ophthalmool 1990 108 259-263.263; Irvine WD, Johnson MW, Heinandez E., et al., Arch Ophthalmol 1991 109 718-722.722; Johnson MW, Olsen KR, Heinandez E., Retina, 1991 11 250-258.258). Therefore, the liquid pharmaceutical formulation of the present invention is substantially free of arginine (meaning that the formulation is free of arginine or the amount of arginine is below the concentration / content that may be toxic (by acting as a carrier of tissue plasminogen activator (t-PA))) or free of arginine. Low viscosity is crucial to achieve a commercial-scale production process (concentration by ultrafiltration) and to ensure easy and convenient intravitreal injection (injection (gliding) force of less than 20N, in particular less than 15N at an injection speed of 50mm / min). It has been demonstrated that the liquid pharmaceutical formulation of the present invention having a viscosity of less than 15mPas can be injected through a 30G injection needle with an injection force of less than 5N within an injection time of 5s. For this purpose, the pharmaceutical formulation of the bispecific anti-VEGF / ANG2 antibody is a liquid isotonic formulation having a viscosity of 15mPas or less, a turbidity of 25FTU or less, an osmotic pressure of 300mOsm / kg±50mOsm / kg and substantially free of visible particles. To avoid the formation of any visible particles, the liquid pharmaceutical formulation of the present invention is substantially free of calcium chloride (meaning that the formulation does not contain calcium chloride, or contains calcium chloride in an amount lower than the concentration / content that may contribute to the formation of visible particles, so that the formulation remains / substantially free of visible particles) or does not contain calcium chloride.
[0209] The terms "ocular vascular disease" and "vascular eye disease" are used interchangeably herein and include, but are not limited to, intraocular neovascular syndromes such as diabetic retinopathy, diabetic macular edema, retinopathy of prematurity, neovascular glaucoma, retinal vein occlusion, central retinal vein occlusion, macular degeneration, age-related macular degeneration, retinitis pigmentosa, retinal angiomatous proliferation, macular telangiectasia, ischemic retinopathy, iris neovascularization, intraocular neovascularization, corneal neovascularization, retinal neovascularization, choroidal neovascularization, and retinal degeneration. (Garner, A., Vascular diseases, In: Pathobiology of ocular disease, A dynamic approach, Garner, A. and Klintworth, GK, eds., 2nd edition, Marcel Dekker, New York (1994), pp. 1625-1710). As used herein, an ocular vascular disorder refers to any pathological condition characterized by altered or unregulated proliferation and invasion of new blood vessels into ocular tissues such as the retina or corneal structure. In one embodiment, the ocular vascular disease is selected from the group consisting of wet age-related macular degeneration (wet AMD) (also known as neovascular age-related macular degeneration (nAMD)), diabetic macular edema (DME), diabetic retinopathy (DR), non-proliferative diabetic retinopathy (NPDR), proliferative diabetic retinopathy (PDR), cystoid macular edema (CME), vasculitis (e.g., central retinal vein occlusion), retinal vein occlusion (RVO), central retinal vein occlusion (CRVO), papilledema, retinitis, conjunctivitis, uveitis, choroiditis, multifocal choroiditis, ocular histoplasmosis, blepharitis, dry eye ( Disease), and other ophthalmic diseases, wherein the ocular disease or disorder is associated with ocular neovascularization, vascular leakage and / or retinal edema, in particular wet age-related macular degeneration (wet AMD) (also known as neovascular age-related macular degeneration (nAMD)), diabetic macular edema (DME), diabetic retinopathy (DR), non-proliferative diabetic retinopathy (NPDR), proliferative diabetic retinopathy (PDR), cystoid macular edema (CME), vasculitis (e.g. central retinal vein occlusion), retinal vein occlusion (RVO), central retinal vein occlusion (CRVO). Therefore, the use and methods of the anti-VEGF / ANG2 bispecific antibodies as described herein can be used to prevent and treat wet AMD (also known as neovascular age-related macular degeneration (nAMD)), DME, DR, NPDR, PDR, preferably wet AMD, DME and RVO, and also preferably wet AMD. In some embodiments, the ocular vascular disease is selected from the group consisting of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), diabetic retinopathy (DR), and retinopathy of prematurity (ROP).
[0210] Other diseases associated with corneal neovascularization include, but are not limited to, epidemic keratoconjunctivitis, vitamin A deficiency, excessive contact lens wear, atopic keratitis, superior limbal keratitis, pterygium sicca, sjogrens, rosacea, phlyctenulosis, syphilis, mycobacterial infection, chemical burns, bacterial ulcers, fungal ulcers, herpes simplex infection, herpes zoster infection, protozoan infection, Kaposi's sarcoma, molluscum corneal ulcer, Terrien's marginal degeneration, marginal keratolysis, rheumatoid arthritis, systemic lupus erythematosus, polyarteritis, trauma, Wegenerssarcoidosis, scleritis, Steven's Johnson disease, pemphigoid radial keratotomy, and corneal transplant rejection.
[0211] Diseases associated with retinal / choroidal neovascularization include, but are not limited to, diabetic retinopathy, macular degeneration, sickle cell anemia, sarcoidosis, syphilis, pseudoxanthoma elasticum, Paget's disease, venous occlusion, arterial occlusion, carotid occlusive disease, chronic uveitis / vitritis, mycobacterial infection, Lyme disease, systemic lupus erythematosus, retinopathy of prematurity, retinitis pigmentosa, retinal edema (including macular edema), Eales disease, Bechets disease, infections causing retinitis or choroiditis, presumed ocular histoplasmosis, Best disease, myopia, optic pits, Stargart disease, pars planitis, chronic retinal detachment, hyperviscosity syndrome, toxoplasmosis, trauma, and post-laser complications. Other diseases include, but are not limited to, diseases associated with erythema (corner neovascularization), and diseases caused by abnormal proliferation of fibrovascular or fibrous tissue (including various forms of proliferative vitreoretinopathy).
[0212] Retinopathy of prematurity (ROP) is an eye disease that affects premature infants. The disease is thought to be caused by disturbed growth of blood vessels in the retina, which may lead to scarring and retinal detachment. ROP may be mild and may resolve spontaneously, but in severe cases it may lead to blindness. Therefore, all premature infants are at risk of developing ROP, and very low birth weight is an additional risk factor. Both oxygen toxicity and relative hypoxia may contribute to the development of ROP.
[0213] Macular degeneration is a medical disease, primarily seen in older people, in which the center of the inner layer of the eye (an area called the macula of the retina) thins, shrinks, and in some cases bleeds. The disease can lead to a loss of central vision, resulting in an inability to see fine detail, read, or recognize faces. According to the American Academy of Ophthalmology, the disease is currently the leading cause of central vision loss (blindness) in people over the age of 50 in the United States. Although certain macular dystrophies that affect younger people are sometimes referred to as macular degeneration, the term usually refers to age-related macular degeneration (AMD or ARMD).
[0214] As used herein, "age-related macular degeneration (AMD)" refers to a serious eye disease when the small central part of the retina (called the macula) degenerates. Wet AMD (wet AMD (wAMD), also known as neovascular AMD (nAMD)) is a late-stage AMD characterized by abnormal blood vessel growth in the choroid beneath the macula. This is called choroidal neovascularization. These blood vessels cause blood and fluid to leak into the retina, causing visual distortion, making straight lines look wavy, as well as blind spots and central vision loss. These abnormal blood vessels eventually form scars, leading to permanent central vision loss. Symptoms of AMD include the presence of a dark, fuzzy area in the center of vision; and a weakened or altered color vision. AMD can be detected in a routine eye exam. One of the most common early symptoms of macular degeneration is the presence of tiny yellow deposits or pigment clumps in the form of drusen under the retina.
[0215] Retinitis pigmentosa (RP) is a group of inherited eye diseases. Night blindness often precedes tunnel vision by years or even decades in the development of RP symptoms. Many people with RP do not become legally blind until their 40s or 50s and retain some vision throughout their lives. Others may become completely blind as a result of RP, and in some cases as early as early childhood. The progression of RP varies from case to case. RP is an inherited retinal dystrophy, which belongs to a group of genetic diseases in which abnormalities of the retina's photoreceptors (rods and cones) or the retinal pigment epithelium (RPE) lead to progressive vision loss. Affected individuals first experience poor dark adaptation or night blindness (night blindness), followed by a reduction in peripheral visual field (called tunnel vision), and sometimes a loss of central vision late in the disease course.
[0216] Macular edema occurs when fluid and protein deposits accumulate above or below the eye's macula, the yellow central area of the retina, causing it to thicken and swell. Since the macula is located near the center of the retina at the back of the eye, swelling can distort a person's central vision. This area houses the tightly packed cones that provide sharp, clear central vision, allowing a person to see shapes, colors, and details within a realistic range. Cystic macular edema is a type of macular edema that includes cyst formation.
[0217] As used herein, "diabetic macular edema" (DME) refers to a serious eye disease that affects people with diabetes (type 1 or type 2). When blood vessels in the retina leak into the macula and fluid and protein deposits accumulate above or below the macula (i.e., the yellow central area of the retina) and cause thickening and swelling, macular edema occurs. Since the macula is located near the center of the retina at the back of the eyeball, swelling may distort a person's central vision. The main symptoms of DME include, but are not limited to, blurred vision, floating, loss of contrast, diplopia, and eventual vision loss. The pathological characteristics of DME are the destruction of the blood-retinal barrier (which normally prevents water from moving in the retina), thereby causing fluid to accumulate in the retinal tissue, and there is retinal thickening. DME is currently diagnosed in an eye exam, which consists of a visual acuity test (determining the smallest letter a person can read on a standard chart), a dilated eye exam (used to check for symptoms of the disease), imaging tests (such as optical coherence tomography (OCT) or fluorescein angiography (FA)) and a tonometer (an instrument for measuring intraocular pressure). The following studies are also performed to determine treatment methods: optical coherence tomography (OCT), fluorescein angiography, and color stereo fundus photography. DME can be roughly divided into two main categories: focal DME and diffuse DME. Focal DME is characterized by the presence of specific areas of separation and obvious leakage in the macular area, where the macular blood flow is sufficient. Diffuse DME is caused by leakage of the entire capillary bed surrounding the macula, and this leakage is caused by the breakdown of the blood-retinal barrier inside the eye. In addition to focal DME and diffuse DME, DME is also divided into clinically significant macular edema (CSME), non-CSME, and centrally involved CSME (CSME-CI, which involves the fovea) based on clinical examination results. The present invention includes methods for treating the above-mentioned categories of DME.
[0218] In one embodiment of the present invention, the ocular vascular disease is selected from the group consisting of: wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), diabetic retinopathy (DR), non-proliferative diabetic retinopathy (NPDR), proliferative diabetic retinopathy (PDR), vasculitis (e.g., retinal vein occlusion (RVO) and central retinal vein occlusion (CRVO)).
[0219] In one embodiment, the ocular vascular disease is selected from the group consisting of diabetic retinopathy (DR), diabetic macular edema (DME), retinal vein occlusion (RVO), central retinal vein occlusion (CRVO), macular degeneration, wet age-related macular degeneration (wet AMD), retinopathy of prematurity (ROP), neovascular glaucoma, retinitis pigmentosa (RP), retinal angiomatous proliferation, macular telangiectasia, ischemic retinopathy, iris neovascularization, intraocular neovascularization, corneal neovascularization, retinal neovascularization, choroidal neovascularization and retinal degeneration, specifically selected from the group consisting of diabetic retinopathy (DR), diabetic macular edema (DME), retinal vein occlusion (RVO), central retinal vein occlusion (CRVO), wet age-related macular degeneration (wet AMD).
[0220] In one embodiment of the present invention, the ocular vascular disease is diabetic retinopathy (DR).
[0221] In one embodiment of the present invention, the ocular vascular disease is diabetic macular edema (DME).
[0222] In one embodiment of the present invention, the ocular vascular disease is retinal vein occlusion (RVO).
[0223] In one embodiment of the present invention, the ocular vascular disease is central retinal vein occlusion (CRVO).
[0224] In one embodiment of the present invention, the ocular vascular disease is retinopathy of prematurity (ROP).
[0225] In one embodiment of the invention, the ocular vascular disease is macular degeneration.
[0226] In one embodiment of the invention, the ocular vascular disease is age-related macular degeneration (AMD).
[0227] In one embodiment of the invention, the ocular vascular disease is wet age-related macular degeneration (wAMD).
[0228] In one embodiment of the present invention, the ocular vascular disease is choroidal neovascularization.
[0229] Application
[0230] The liquid pharmaceutical preparation according to the present invention can be administered by intravitreal (IVT) methods, such as those known in the pharmaceutical art (e.g., using an appropriate syringe). For intravitreal injection, the injection volume is generally 50 μL to 100 μL. Intravitreal injection is performed using a disposable syringe and a 30G (25G to 30G) injection needle or a prefilled syringe equipped with an appropriate injection needle. A filter needle with a pore size of 5 μm can be used to draw the liquid preparation from the vial containing the preparation. Intravitreal injection techniques are described, for example, in the following literature: D. Yorston, Community Eye Health. 2014; 27(87): 47.
[0231] To this end, the pharmaceutical formulation of the bispecific anti-VEGF / ANG2 antibody is a liquid isotonic formulation having a viscosity of 15 mPas or less, a turbidity of 25 FTU or less, an osmotic pressure of 300 mOsm / kg ± 50 mOsm / kg, and is substantially free of visible particles.
[0232] Preparations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes and aseptic manufacturing practices.
[0233] Method for preparing the formulation
[0234] The pharmaceutical preparation according to the present invention can be prepared by processing known methods or processes in the art (e.g., ultrafiltration-diafiltration, dialysis, addition and mixing, lyophilization, reconstitution, and combinations thereof). The preparation examples of the preparation according to the present invention can be found below.
[0235] In one embodiment of the present invention, the pharmaceutical preparation can be produced by the following production method or process, which comprises the following steps:
[0236] 1. Buffer exchange with a diafiltration buffer (comprising histidine-acetate buffer, or histidine-acetate buffer and sodium chloride, or histidine-acetate buffer, sodium chloride and methionine, or histidine-acetate buffer, sodium chloride, methionine and sucrose) by ultrafiltration and diafiltration using a semipermeable membrane with a MWCO (molecular weight cutoff) between 5 kD and 80 kD (30 kD to 50 kD) (30 kD). Typically, the ratio of diafiltration buffer to bulk solution is 5 to 20 (5-10).
[0237] 2. In place of the operation described in 1, the buffer exchange can be achieved by dialysis using a dialysis buffer (comprising histidine-acetate buffer, or histidine-acetate buffer and sodium chloride, or histidine-acetate buffer, sodium chloride and methionine, or histidine-acetate buffer, sodium chloride, methionine and sucrose) and a dialysis membrane having a MWCO between 5 kD and 80 kD (30 kD to 50 kD) (30 kD). Typically, the ratio of dialysis buffer to bulk solution is 5 to 20 (5-10).
[0238] 3. Concentrate the buffer exchanged bulk solution by ultrafiltration to a protein concentration exceeding 120 mg / mL (120 mg / mL to 160 mg / mL or 120 mg / mL to 200 mg / mL) using a diafiltration membrane with a MWCO (molecular weight cutoff) between 5 kD and 80 kD (30 kD to 50 kD) (30 kD).
[0239] 4. The final composition of the pharmaceutical preparation can be adjusted by adding stock solutions of the corresponding excipients or by adjusting the buffer appropriately. The solution is homogenized by mixing.
[0240] Furthermore, the production method or process may comprise the following steps:
[0241] 5. The final prepared solution can be stored frozen at below -20°C (below -40°C).
[0242] 6. Thaw the solution before filling into final primary container
[0243] 7. Mix multiple containers or batches of drug preparations and homogenize them by stirring
[0244] 8. The homogenized drug formulation is filtered through multiple (at least two) sterilizing grade filters with a pore size of at least 0.2 μm or 0.22 μm.
[0245] 9. Under aseptic conditions, fill the sterile filtered solution into sterile vials or prefilled syringes and seal with elastic stoppers (push stoppers and end caps, respectively).
[0246] 10. Check the primary container after filling for defects and visible particles
[0247] 11. Assemble the prefilled syringe with the corresponding device components, package them into a sterile barrier system, and sterilize the outer surface.
[0248] 12. Package vials and sterile syringes in final secondary packaging
[0249] The pharmaceutical preparation according to the present invention can also be provided as a lyophilized form or a liquid form reconstituted by the lyophilized form. "Lyophilized form" is prepared by a lyophilization method known in the art. The lyophilized material generally has a residual moisture content of about 0.1% (w / w) to 5% (w / w), and exists in the form of a powder or a physically stable cake. "Reconstituted form" can be obtained by rapidly dissolving the lyophilized material after adding a reconstitution medium. Suitable reconstitution media include, but are not limited to, water for injection (WFI), bacteriostatic water for injection (BWFI), sodium chloride solution (e.g., 0.9% (w / v) NaCl) and glucose solution (e.g., 5% (w / v) glucose).
[0250] Antibody Production
[0251] Anti-VEGF / ANG2 antibodies particularly suitable for use in the present invention are produced by recombinant means. Recombinant production methods are well known in the art and include expression of proteins in prokaryotic and eukaryotic cells, followed by isolation of the antibody, and usually purification to a pharmaceutical purity. To express the above antibodies in host cells, nucleic acids encoding the corresponding modified light and heavy chains are inserted into expression vectors using standard methods. Expression is performed in appropriate prokaryotic or eukaryotic host cells (e.g., CHO cells, NSO cells, SP2 / 0 cells, HEK293 cells, COS cells, PER.C6 cells, yeast or E. coli cells), and the antibody is recovered from the cells (supernatant or cells after lysis). General methods for recombinant production of antibodies are well known in the art and are reviewed in the following papers: Makrides, SC, Protein Expr. Purif. 17 (1999) 183-202; Geisse, S. et al., Protein Expr. Purif. 8 (1996) 271-282; Kaufman, RJ, Mol. Biotechnol 16 (2000) 151-160; Werner, RG, Drug Res. 48 (1998) 870-880. A method for preparing an antibody for use in the present invention comprises the following steps: a) transforming a host cell with a vector comprising a nucleic acid molecule encoding the antibody; b) culturing the host cell under conditions that allow synthesis of the antibody molecule; and c) recovering the antibody molecule from the culture medium.
[0252] Antibodies are suitable for separation from culture medium by conventional immunoglobulin purification methods (such as protein A-Sepharose, hydroxyapatite chromatography, gel electrophoresis, dialysis or affinity chromatography). DNA and RNA encoding monoclonal antibodies are easy to be separated and sequenced by conventional methods. Hybridoma cells can be used as the source of such DNA and RNA. Once separated, DNA can be inserted into expression vectors, which are then transfected into host cells such as HEK293 cells, CHO cells or myeloma cells that do not produce immunoglobulins in addition, to obtain the synthesis of recombinant monoclonal antibodies in host cells.
[0253] The amino acid sequence variants (or mutants) of bispecific antibodies are prepared by introducing appropriate nucleotide changes into antibody DNA or by nucleotide synthesis. However, such modifications can only be carried out within a very limited range. For example, the modification does not change the above-mentioned antibody properties, such as IgG isotype and antigen binding, but can improve the yield of recombinant production, protein stability or promote purification.
[0254] The term "host cell" as used in this application refers to any kind of cell system that can be engineered to produce the antibodies contained in the formulations of the present invention. In one embodiment, HEK293 cells and CHO cells are used as host cells.
[0255] As used herein, the terms "cell", "cell line" and "cell culture" are used interchangeably, and all such designations include progeny. Thus, the terms "transformants" and "transformed cells" include the primary subject cell and cultures derived from that cell regardless of the number of transfers. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or unintentional mutations. Variant progeny having the same function or biological activity as screened in the original transformed cell are included.
[0256] Expression in NS0 cells is described, for example, in Barnes, LM et al., Cytotechnology 32 (2000) 109-123; Barnes, LM et al., Biotech. Bioeng. 73 (2001) 261-270. Transient expression is described, for example, in Durocher, Y. et al., Nucl. Acids. Res. 30 (2002) E9. Cloning of variable domains is described, for example, in Orlandi, R. et al., Proc. Natl. Acad. Sci. USA 86 (1989) 3833-3837; Carter, P. et al., Proc. Natl. Acad. Sci. USA 89 (1992) 4285-4289; and Norderhaug, L. et al., J. Immunol. Methods 204 (1997) 77-87. A preferred transient expression system (HEK 293) is described, for example, in Schlaeger, E.-J. and Christensen, K., Cytotechnology 30 (1999) 71-83; and Schlaeger, E.-J., J. Immunol. Methods 194 (1996) 191-199.
[0257] Suitable control sequences for prokaryotes include, for example, a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, enhancers, and polyadenylation signals.
[0258] When a nucleic acid is placed in a functional relationship with another nucleic acid sequence, the nucleic acid is "operably linked". For example, the DNA of a presequence or secretory leader is operably linked to the DNA for a polypeptide (if it is expressed as a preprotein that participates in the secretion of the polypeptide); a promoter or enhancer is operably linked to a coding sequence that affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence that is positioned to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are continuous, and are continuous and in the reading frame for the secretory leader sequence. However, enhancers do not have to be continuous. The connection is accomplished by connecting at a convenient restriction site. If such a site does not exist, a synthetic oligonucleotide adapter or linker is used according to conventional practice.
[0259] Antibody purification is performed to eliminate cellular components or other contaminants (e.g., other cellular nucleic acids or proteins) by standard techniques, including alkaline / SDS treatment, CsCl banding, column chromatography, agarose gel electrophoresis, and other techniques well known in the art. See Ausubel, F. et al., ed., Current Protocols in Molecular Biology (Greene Publishing and Wiley Interscience, New York, 1987). Various protein purification methods are well established and widely used, such as microprotein affinity chromatography (e.g., protein A or protein G affinity chromatography), ion exchange chromatography (e.g., cation exchange (carboxymethyl resin), anion exchange (aminoethyl resin) and mixed mode exchange), thiophilic adsorption (e.g., using β-mercaptoethanol and other SH ligands), hydrophobic interaction or aromatic adsorption chromatography (e.g., using phenyl-agarose, hetero-nitrogen aryl resins or m-aminophenylboronic acid), metal chelate affinity chromatography (e.g., using Ni(II)-affinity materials and Cu(II)-affinity materials), size exclusion chromatography and electrophoresis methods (such as gel electrophoresis, capillary electrophoresis) (Vijayalakshmi, MA, Appl. Biochem. Biotech. 75 (1998) 93-102).
[0260] Amino acid sequences disclosed in this application:
[0261] SEQ ID NO: Description
[0262] 1 <vegf>Heavy chain variable domain CDR3 < / vegf> 2 <vegf>Heavy chain variable domain CDR2 < / vegf> 3 <vegf>Heavy chain variable domain CDR1 < / vegf> 4 <vegf>Light chain variable domain CDR3 < / vegf> 5 <vegf>Light chain variable domain CDR2 < / vegf>
[0263] SEQ ID NO: Description
[0264]
[0265] List embodiments of the present invention below:
[0266] 1. A liquid pharmaceutical preparation comprising:
[0267] - 20 mg / mL to 150 mg / mL of a bispecific anti-VEGF / ANG2 antibody comprising
[0268] A heavy chain constant region containing human IgG1 subclass (in one embodiment, comprising 30 mg / mL
[0269] ±4.5mg / mL or 120mg / mL±18mg / mL),
[0270] -15mM to 35mM sodium chloride (in one embodiment, including 25mM ± 5mM;
[0271] In one embodiment, it comprises 25 mM ± 3.75 mM sodium chloride; in particular, it comprises
[0272] Contains 25mM ± 2.5mM sodium chloride),
[0273] -15 mM to 25 mM histidine acetate buffer (in one embodiment, comprising 20
[0274] mM ± 3 mM histidine acetate buffer; in one embodiment, comprising 20
[0275] mM ± 2mM histidine acetate buffer),
[0276] Its pH value is 5.5±0.5 (in one embodiment, the pH value is 5.5±0.3; in particular, the pH value is 5.5±0.2);
[0277] The bispecific anti-VEGF / ANG2 antibody is bivalent and comprises a first antigen binding site that specifically binds to human VEGF and a second antigen binding site that specifically binds to human ANG-2, wherein
[0278] i) the first antigen-binding site that specifically binds to VEGF comprises a CDR3H region of SEQ ID NO: 1, a CDR2H region of SEQ ID NO: 2, and a CDR1H region of SEQ ID NO: 3 in the heavy chain variable domain, and a CDR3L region of SEQ ID NO: 4, a CDR2L region of SEQ ID NO: 5, and a CDR1L region of SEQ ID NO: 6 in the light chain variable domain; and
[0279] ii) said second antigen-binding site that specifically binds to ANG-2 comprises in the heavy chain variable domain a CDR3H region of SEQ ID NO: 9, a CDR2H region of SEQ ID NO: 10, and a CDR1H region of SEQ ID NO: 11, and in the light chain variable domain a CDR3L region of SEQ ID NO: 12, a CDR3L region of SEQ ID NO: 13, a CDR2H region of SEQ ID NO: 14, and a CDR1H region of SEQ ID NO: 15;
[0280] The CDR2L region of SEQ ID NO:13 and the CDR1L region of SEQ ID NO:14,
[0281] And among them
[0282] iii) the bispecific antibody comprises a heavy chain constant region of human IgG1 subclass comprising the mutations I253A, H310A and H435A and the mutations L234A, L235A and P329G (numbering according to the Kabat EU index).
[0283] 2. The pharmaceutical formulation according to embodiment 1, wherein the bispecific anti-VEGF / ANG2 antibody is bivalent and comprises a first antigen binding site that specifically binds to human VEGF and a second antigen binding site that specifically binds to human ANG-2, wherein
[0284] i) the first antigen binding site that specifically binds to VEGF comprises the amino acid sequence of SEQ ID NO: 7 as the heavy chain variable domain VH and the amino acid sequence of SEQ ID NO: 8 as the light chain variable domain VL, and
[0285] ii) the second antigen-binding site that specifically binds to ANG-2 comprises the amino acid sequence of SEQ ID NO: 15 as the heavy chain variable domain VH and the amino acid sequence of SEQ ID NO: 16 as the light chain variable domain VL.
[0286] 3. The pharmaceutical formulation according to embodiment 2, wherein the bispecific anti-VEGF / ANG2 antibody is bivalent and comprises a first antigen binding site that specifically binds to human VEGF and a second antigen binding site that specifically binds to human ANG-2, wherein
[0287] in
[0288] iv) in the heavy chain constant region, S354C and T366W mutations are contained in one CH3 domain, and Y349C, T366S, L368A and Y407V mutations are contained in the other CH3 domain (numbering according to the Kabat EU index).
[0289] 4. The pharmaceutical formulation of any one of embodiments 1 to 3, wherein the bispecific anti-VEGF / ANG2 antibody is bivalent and comprises the amino acid sequence of SEQ ID NO: 17, the amino acid sequence of SEQ ID NO: 18, the amino acid sequence of SEQ ID NO: 19, and the amino acid sequence of SEQ ID NO: 20.
[0290] 5. The pharmaceutical formulation according to any one of embodiments 1 to 3, wherein the bispecific anti-VEGF / ANG2 antibody is fariximab.
[0291] 6. The pharmaceutical preparation according to embodiment 1, wherein the preparation comprises
[0292] -120 mg / mL ± 18 mg / mL bispecific anti-VEGF / ANG2 antibody (particularly 120
[0293] mg / mL ± 12 mg / mL bispecific anti-VEGF / ANG2 antibody).
[0294] 7. The pharmaceutical formulation according to any one of claims 1 to 7, for intravitreal administration.
[0295] 8. The pharmaceutical formulation of any one of embodiments 1 to 6, wherein the formulation is substantially free of visible particles.
[0296] 9. The pharmaceutical formulation of any one of embodiments 1 to 8, wherein the formulation further comprises -1 mM to 20 mM of at least one stabilizer (in one embodiment, selected from sugars, polyols, and amino acids).
[0297] 10. The pharmaceutical formulation of any one of embodiments 1 to 8, wherein the formulation further comprises -7.0 mM ± 2.0 mM methionine (in one embodiment, 7.0 mM ± 1.0
[0298] mM methionine; in one embodiment, comprising 7.0 mM ± 0.7 mM methionine).
[0299] 11. The pharmaceutical formulation according to any one of embodiments 1 to 10, wherein the formulation further comprises
[0300] - 0.01% to 0.07% surfactant (in one embodiment selected from polysorbate 20, polysorbate 80 or poloxamer).
[0301] 12. The pharmaceutical formulation according to any one of embodiments 1 to 10, wherein the formulation further comprises
[0302] -0.04% (w / v) ± 0.02 (w / v) polysorbate 20 (in one embodiment, comprising 0.03% (w / v) to 0.07% (w / v); in one embodiment, comprising 0.04% (w / v)
[0303] ±0.01 (w / v); in one embodiment, comprising about 0.04% (w / v)).
[0304] 13. The pharmaceutical formulation according to any one of embodiments 1 to 12, wherein the formulation further comprises
[0305] -50 mM to 250 mM tonicity agent (in one embodiment, the tonicity agent is selected from sucrose, trehalose and sorbitol).
[0306] 14. The pharmaceutical formulation according to any one of embodiments 1 to 12, wherein the formulation further comprises
[0307] -160 mM ± 24 mM sucrose (in one embodiment, comprising 160 mM ± 16
[0308] mM; in one embodiment, comprising about 160 mM).
[0309] 15. The pharmaceutical formulation of any one of embodiments 1 to 14, wherein the formulation has a viscosity of 20 mPas or less (in one embodiment, 17 mPas or less; in one embodiment, 16 mPas or less; in one embodiment, about 15 mPas or less; in one embodiment, 15 mPas or less).
[0310] 16. The pharmaceutical formulation of any one of embodiments 1 to 15, wherein the formulation has a turbidity of 30 FTU or less (in one embodiment, 27 FTU or less; in one embodiment, 26 FTU or less; in one embodiment, about 25 FTU or less; in one embodiment, 25 FTU or less).
[0311] 17. The pharmaceutical formulation of any one of embodiments 1 to 16, wherein the formulation has an ionic strength between 20 and 50 (in one embodiment, between 30 and 50; in one embodiment, between 30 and 45; in one embodiment, 30±10).
[0312] 18. The pharmaceutical formulation of any one of embodiments 1 to 17, for intravitreal administration, wherein the formulation is substantially free of calcium chloride (or contains no calcium chloride).
[0313] 19. The pharmaceutical formulation of any one of embodiments 1 to 17, for intravitreal administration, wherein the formulation is substantially free of arginine (or contains no arginine).
[0314] 20. The pharmaceutical formulation of any one of embodiments 1 to 17 for intravitreal administration, wherein the formulation is substantially free of arginine and calcium chloride (or is free of arginine and calcium chloride).
[0315] 21. The pharmaceutical formulation according to any one of embodiments 1 to 5 and embodiments 7 to 20, wherein the formulation comprises (at least) the following components or (at least) consists of the following components:
[0316] -20 mg / mL to 150 mg / mL of a bispecific anti-VEGF / ANG2 antibody (in one embodiment, comprising 30 mg / mL±4.5 mg / mL or 120 mg / mL±18 mg / mL,
[0317] In particular, 120 mg / mL ± 12 mg / mL);
[0318] -15mM to 35mM sodium chloride (in one embodiment, including 25mM±5mM; in one embodiment, including 25mM±3.75mM sodium chloride; in particular including 25mM±2.5mM sodium chloride);
[0319] -15 mM to 25 mM histidine acetate buffer (in one embodiment, comprising 20
[0320] mM ± 3 mM histidine acetate buffer; in one embodiment, comprising 20
[0321] mM ± 2mM histidine acetate buffer);
[0322] -7.0 mM ± 2.0 mM methionine (in one embodiment, comprising 7.0 mM ± 1.0
[0323] mM methionine; in one embodiment, comprising 7.0 mM ± 0.7 mM methionine);
[0324] -0.03% (w / v) to 0.07% (w / v) polysorbate 20 (in one embodiment, 0.04% (w / v) ± 0.02 (w / v); in one embodiment, 0.04% (w / v) ±
[0325] 0.01 (w / v); in one embodiment, comprising about 0.04% (w / v);
[0326] -160 mM ± 24 mM sucrose (in one embodiment, comprising 160 mM ± 16
[0327] mM; in one embodiment, comprising about 160 mM);
[0328] - Water (for (ophthalmic) injection);
[0329] Its pH value is 5.5±0.5 (in one embodiment, the pH value is 5.5±0.3; in particular, the pH value is 5.5±0.2);
[0330] 22. The pharmaceutical formulation according to any one of embodiments 1 to 21, wherein the formulation is a stable formulation.
[0331] 23. The pharmaceutical formulation of any one of embodiments 1 to 21, wherein the high molecular weight substance (HMW) content of the bispecific antibody in the pharmaceutical formulation is less than 10% (in one embodiment, less than 5%) after storage of the pharmaceutical formulation at 25°C for 8 weeks or after storage at 25°C for 52 weeks.
[0332] 24. The pharmaceutical formulation according to any one of embodiments 1 to 21, wherein after storage of the pharmaceutical formulation at 2-8°C for 2 years (or after storage at 2-8°C for 3 years), the main peak of the bispecific antibody in the pharmaceutical formulation is more than 50% and the high molecular weight substances (HMW) of the bispecific antibody are less than 10% (after storage of the pharmaceutical formulation at 2-8°C for 2 years (or after storage at 2-8°C for 3 years), the main peak of the bispecific antibody in the pharmaceutical formulation is more than 55% and the high molecular weight substances (HMW) of the bispecific antibody are less than 7%).
[0333] 25. The pharmaceutical formulation of any one of embodiments 1 to 24, wherein the osmotic pressure of the formulation is 300 mOsm / kg ± 100 mOsm / kg (in one embodiment, 300 mOsm / kg ± 50 mOsm / kg).
[0334] 26. The pharmaceutical formulation of any one of embodiments 1 to 25 for use in treating ocular vascular diseases.
[0335] 27. The pharmaceutical preparation for use according to embodiment 26, wherein the ocular vascular disease is selected from the group consisting of diabetic retinopathy (DR), diabetic macular edema (DME), retinal vein occlusion (RVO), central retinal vein occlusion (CRVO), macular degeneration, wet age-related macular degeneration (wet AMD), retinopathy of prematurity (ROP), neovascular glaucoma, retinitis pigmentosa (RP), retinal angiomatous proliferation, macular telangiectasia, ischemic retinopathy, iris neovascularization, intraocular neovascularization, corneal neovascularization, retinal neovascularization, choroidal neovascularization and retinal degeneration, in particular selected from the group consisting of diabetic retinopathy (DR), diabetic macular edema (DME), retinal vein occlusion (RVO), central retinal vein occlusion (CRVO), wet age-related macular degeneration (wet AMD).
[0336] 28. The pharmaceutical preparation for use according to embodiment 26, wherein the ocular vascular disease is diabetic retinopathy.
[0337] 29. The pharmaceutical preparation for use according to embodiment 26, wherein the ocular vascular disease is diabetic macular edema (DME).
[0338] 30. The pharmaceutical preparation for use according to embodiment 26, wherein the ocular vascular disease is retinal vein occlusion (RVO).
[0339] 31. The pharmaceutical preparation for use according to embodiment 26, wherein the retinal vein occlusion is central retinal vein occlusion (CRVO).
[0340] 32. The pharmaceutical preparation for use according to embodiment 26, wherein the ocular vascular disease is macular degeneration.
[0341] 33. The pharmaceutical preparation for use according to embodiment 26, wherein the macular degeneration is age-related macular degeneration (AMD).
[0342] 34. The pharmaceutical preparation for use according to embodiment 26, wherein the macular degeneration is wet age-related macular degeneration (wAMD) (also known as neovascular age-related macular degeneration (nAMD)).
[0343] 35. The pharmaceutical preparation for use according to embodiment 26, wherein the ocular vascular disease is choroidal neovascularization.
[0344] 36. A method for preparing a pharmaceutical formulation according to any one of embodiments 1 to 25,
[0345] The method comprises the following steps:
[0346] The bispecific antibody bulk solution is a) buffer exchanged with a diafiltration buffer by ultrafiltration and diafiltration, or b) buffer exchanged by dialysis using a dialysis buffer comprising histidine-acetate buffer, or histidine-acetate buffer and sodium chloride, or histidine-acetate buffer, sodium chloride and methionine, or histidine-acetate buffer, sodium chloride, methionine and sucrose
[0347] - Concentrate the buffer exchanged bulk solution by ultrafiltration
[0348] - The final composition of the pharmaceutical preparation is adjusted by adding stock solutions of the corresponding excipients or by appropriate adjustment of the buffer and the liquid pharmaceutical preparation is homogenized by mixing.
[0349] 37. A vial comprising the pharmaceutical formulation of any one of embodiments 1 to 25.
[0350] 38. A prefilled syringe comprising the pharmaceutical formulation of any one of embodiments 1 to 25.
[0351] 39. A lyophilized form of the liquid pharmaceutical formulation of any one of embodiments 1 to 25.
[0352] Examples
[0353] The development of a liquid drug product formulation for intravitreal (IVT) administration according to the present invention is as follows.
[0354] Example 1: Materials and Methods
[0355] The bispecific anti-VEGF / ANG2 antibody CrossMAb VEGFang2-0016 (fariximab) prepared and purified according to the method described in WO2014 / 009465 was provided for further experiments initially using a concentration of about 130 mg / mL to 140 mg / mL in 20 mM histidine-HCl buffer (pH 5.5).
[0356] Materials used in the preparation of the drug product (including suppliers) and their primary packaging are provided by
[0357] Table 1 and Table 2.
[0358] Table 1 Chemicals used in formulations
[0359] Chemicals supplier Base without L-histidine Ajinomoto L-Histidine-HCl monohydrate Ajinomoto Sodium acetate – trihydrate Merck Glacial acetic acid Wacker Chemie Sodium chloride Merck <![CDATA[Calcium chloride dihydrate (CaCl2)]]> Applichem sucrose FPS Methionine Ajinomoto Polysorbate 20 Croda Poloxamer BASF
[0360] Table 2 Main packaging
[0361] name supplier 6mL vial, colorless, 20mm Schott Teflon serum stopper D777-1, 20mm Daikyo Aluminum cap and PP cap, 20mm Helvoet (Datwyler) 2mL vial, colorless, 13mm Schott Bottle stopper with Teflon septum D777-1, 13 mm Daikyo Aluminum cap and PP cap, 13mm Helvoet (Datwyler) 1.0mL Prefilled Syringe (PFS) Gerresheimer Buende 1.0mL PFS plunger stopper West 0.5mL Prefilled Syringe (PFS) Nuova Ompi 0.5mL PFS plunger stopper West
[0362] Container Closure Systems
[0363] 2 mL or 6 mL colorless glass vials (Type 1 glass) are closed with rubber stoppers (D 777-1, 13 mm) and aluminum overseals with flip-top caps.
[0364] A 1.0 mL colorless prefilled syringe (Type 1 glass) with a luer cone was closed with a Gerresheimer Buende TELC end cap and a West 4023 / 50 plunger stopper.
[0365] 0.5 mL colorless prefilled syringe (Type 1 glass) with Luer cone closed with Vetter OVS end cap and West 4023 / 50 plunger stopper. Vetter OVS end cap consists of West 4023 / 50 elastomer.
[0366] Size Exclusion Chromatography (SE-HPLC)
[0367] Size exclusion chromatography (SEC) was used to detect soluble high molecular weight substances (aggregates) and low molecular weight (LMW) hydrolysis products in the preparation. The method was performed using TSK-Gel G3000SWXL, 7.8×300mm, 5μm (Tosoh Bioscience, catalog number 08541) or BioSuite 250, 7.8×300mm, 5μm (Waters, catalog number 186002165). 0.2M potassium phosphate, 0.25M KCl (pH 7.0) was used as the mobile phase to separate intact monomers, aggregates and fragments by an isocratic elution curve and detected at a wavelength of 280nm.
[0368] Ion Exchange Chromatography (IE-HPLC)
[0369] Ion exchange chromatography (IEC) is used to detect chemical degradation products that change the net charge of antibodies in the formulation. The method is carried out using YMC BioPro SP-F, 100×4.6mm, 5μm chromatographic column (YMC, catalog number SF00S05-1046WP). 20mM BES (N, N-bis[2-hydroxyethyl]-2-aminoethanesulfonic acid) (pH 6.8) is used as eluent A, and 20mMBES, 488mM NaCl (pH 6.8) is used as eluent B, and its flow rate is 0.8mL / min. Before the sample is injected into the chromatographic column, it is diluted to 3mg / mL with eluent A.
[0370] Gradient Program:
[0371] Time (min) % Mobile phase A % Mobile phase B 0 98 2 5 98 2 35 85 15 35.1 0 100 40 0 100 40.1 98 2 50 98 2
[0372] Turbidity (unit: FTU (=Formazine Turbidity Unit))
[0373] The turbidity of the formulation samples was measured on a Hach 2100AN turbidimeter according to European Pharmacopoeia 2.2.1 "Clarity of liquids and opacity". A sample volume of about 2 mL of the sample solution was transferred to a glass cuvette with an inner diameter of 11 mm. The glass cuvette was placed in the turbidimeter and the turbidity was measured according to the calibration curve of the reference suspension (1 FTU, 3 FTU, 10 FTU, 20 FTU and 100 FTU.
[0374] Viscosity (in mPa)
[0375] The viscosity of the formulation samples was measured using an Anton Paar Physica MCR 301 rotational rheometer with a cone of 25 mm–0.5° and a shear rate of 1000 s -1 , and the temperature is 20°C.
[0376] Visible particles
[0377] The samples in the vials were visually inspected with the aid of a 2x magnifying glass on a Seidenader inspection device V90-T. The illumination sources L1, L2 and L3 were adjusted to setting 5. The samples in the vials were inspected for the presence of particles during the rotational movement.
[0378] Protein concentration (in mg / mL).
[0379] The protein concentration of the formulation sample was measured by ultraviolet (UV) light absorption on a Perkin Elmer UV / Vis photometer λ35. The formulation sample was diluted with 20 mM L-histidine-acetate buffer (pH 5.5) to a protein concentration of about 0.5 mg / mL and then placed in a 1 cm thick cuvette. The UV absorbance of the cuvette was measured at wavelengths of 280 nm and 320 nm.
[0380] The protein concentration was calculated from the UV absorbance measured at 280 nm and 320 nm (A280 and A320, respectively), the extinction coefficient (E) of 1.70 mL / (mg x cm), the thickness (d) of 1 cm, and the dilution factor (DF) corresponding to the actual dilution using the following formula:
[0381]
[0382] Osmotic pressure
[0383] The osmotic pressure of the formulation samples was measured on an Osmomat 030 3P osmometer from Gonotec based on the freezing point depression principle.
[0384] pH
[0385] The pH of the formulation samples was measured potentiometrically using a glass electrode.
[0386] Example 2: pH / buffer screening I
[0387] set up
[0388] The range of pH / buffer screening was used to select the optimal pH and buffer for commercial formulations of anti-VEGF / ANG2 antibodies and to select formulations with low viscosity, low turbidity and good stability behavior (thus reducing the formation of soluble aggregates and charged variants).
[0389] The first part of the pH / buffer screening included three buffer systems: L-histidine / L-histidine hydrochloride (His / His-HCl), L-histidine acetate (His / acetate), and sodium acetate (Na / acetate), with a pH range between 5.3 and 6.5, a buffer strength range between 7 mM and 300 mM, and an ionic strength range between 5 and 86. The active formulation settings are shown in Table 3.
[0390] Table 3 Formulation Code: pH / Buffer Screening Part I
[0391]
[0392] Materials and Methods
[0393] The materials used in the preparation of the formulations and their primary packaging are provided in Tables 1 and 2.
[0394] The drug substance was buffer exchanged by dialysis using a Slide-A-Lyzer G2 (Thermo Scientific) with a molecular weight cutoff of 10 kD against the buffer systems listed in Table 3. Thus, 42 mL of drug substance was filled into the dialysis apparatus and three buffer exchanges were performed with 5 L of dialysis buffer.
[0395] Optionally, if the protein concentration after dialysis was below 120 mg / mL, the drug substance was concentrated by centrifugation (20° C., 4000 rpm) using an Amicon Ultra 15, Ultracel 10K (Millipore) device.
[0396] Then, the dialyzed and optionally concentrated API was diluted with dialysis buffer to a target protein concentration of 120 mg / mL to obtain a final drug solution.
[0397] Each drug solution was filtered through a 0.22 μm Sterivex GV (Millipore) filter and filled into clean and sterile 6 mL vials with a fill volume of 2.7 mL. The vials were stoppered and crimped.
[0398] Analytical methods
[0399] The analytical testing methods for turbidity and viscosity are described in Example 1.
[0400] result
[0401] FIG1 compares the turbidity and viscosity results of the formulations from pH / buffer screen I.
[0402] In general, formulations with high ionic strength (e.g., 4, 14, 10, 3, 8, and 18) exhibit high turbidity (above 30 FTU) and low viscosity (about 10 mPas). In contrast, formulations with low ionic strength have high viscosity (about 25 to 40 mPas) and low turbidity (below 10 FTU). Surprisingly, formulations using the buffer system histidine acetate (13, 6, 4, 14) were identified as having low viscosities of about 10 mPas and turbidities of less than 25 FTU.
[0403] in conclusion
[0404] The viscosity and turbidity of the formulations resulting from pH / buffer screen I were measured. Surprisingly, formulations employing a histidine-acetate buffer system and having an ionic strength of 45.5 or greater exhibited low viscosity and reduced turbidity values.
[0405] Example 3: pH / buffer screening II
[0406] set up
[0407] The range of pH / buffer screening was used to select the optimal pH and buffer for the formulation of the anti-VEGF / ANG2 antibody CrossMAb VEGFang2-0016 (Fariximab) anti-VEGF / ANG2 antibody, and to select a formulation with low viscosity, low turbidity and good stability behavior (thereby reducing the formation of soluble aggregates and charged variants).
[0408] The second part of the pH / buffer screen was designed based on the results from pH / buffer screen I and included the buffer L-histidine-acetate (His / acetate), a pH range between 5.5 and 6.0, and a buffer strength range between 14 mM and 59 mM. The ionic strength of the formulation was changed by increasing the buffer strength or adding sodium chloride (NaCl) or calcium chloride (CaCl2) to bring the ionic strength between 10 and 50. The settings for the active formulations are shown in Table 4.
[0409] Table 4 Formulation Code: pH / Buffer Screening Part II
[0410]
[0411] Materials and Methods
[0412] The materials used in the preparation of the formulations and their primary packaging are provided in Tables 1 and 2.
[0413] The drug substance was buffer exchanged by ultrafiltration-diafiltration with the buffer systems listed in Table 4 using a Labscale TTF (Millipore) equipped with a semipermeable membrane with a molecular weight cut-off of 30 kD. Thus 120 mL of drug substance was filled into the Labscale system and buffer exchanged with 1050 mL of diafiltration buffer.
[0414] After buffer exchange, the drug substance was concentrated in a Labscale system to a protein concentration of approximately 150 mg / mL.
[0415] The concentrated drug substance was then diluted with the corresponding stock solutions of buffer and saline to a target protein concentration of 120 mg / mL to obtain the final drug solution as shown in Table 4.
[0416] Each drug solution was filtered through a 0.22 μm Sterivex GV (Millipore) filter and filled into clean and sterile 6 mL vials with a fill volume of 2.7 mL. The vials were stoppered and crimped.
[0417] Analytical methods
[0418] Turbidity, viscosity and SE-HPLC analytical detection methods are described in Example 1.
[0419] Stability Study Program
[0420] The formulation was stable for 8 weeks at 2-8°C and 25°C. Samples were drawn at the beginning of the stability study and after 8 weeks of storage and analyzed.
[0421] result
[0422] Figure 2 compares the turbidity and viscosity results from the second part of the pH / buffer screening. In general, turbidity increased with increasing ionic strength, and turbidity increased at pH 6.0 compared to turbidity at pH 5.5. In addition, the presence of sodium chloride also resulted in higher turbidity. Viscosity also decreased at pH 5.5 compared to pH 6. In addition, an ionic strength of at least 30 helped to reduce viscosity to a level of approximately 15 mPas. Comparing the effects of different salts on viscosity revealed that calcium chloride or higher buffer strengths were more effective in reducing viscosity than sodium chloride.
[0423] Considering the two goals of reducing turbidity and viscosity, a formulation having an ionic strength of at least 30 and a pH of 5.5 exhibited a reduced turbidity level of about 20 FTU and a viscosity of about 15 mPas.
[0424] Figure 3 The aggregate content (HMWS) of the pH / buffer screen II formulations at the beginning (=0) was compared with the content after 8 weeks of storage at 5°C and 25°C. In general, the HMW content increased with increasing ionic strength. Comparing the effects of different salts, it was found that high buffer strength or the presence of sodium chloride resulted in a slower increase in aggregates than in the presence of sodium chloride. The lower pH (5.5) had less effect on reducing aggregate formation.
[0425] in conclusion
[0426] The formulation with a pH of 5.5 and an ionic strength of 30 provides the best balance of reduced turbidity, low viscosity and reduced aggregate formation. The ionic strength can be adjusted with higher buffer strength or the addition of salts (sodium chloride and calcium chloride). In general, higher buffer strength or the presence of calcium chloride results in better turbidity and viscosity behavior.
[0427] Example 4: Surfactant Screening
[0428] set up
[0429] The scope of surfactant screening was used to select surfactant type and surfactant concentration for the anti-VEGF / ANG2 antibody CrossMAb VEGFang2-0016 (fariximab).
[0430] The formulation matrix was 120 mg / mL VEGF / Ang-2 antibody, 20 mM L-histidine-acetate buffer (pH 5.5), 25 mM sodium chloride, and 180 mM sucrose, which was based on the results of pH / buffer screens I and II and enabled an isotonic formulation with a target osmotic pressure of 300 mOsm / kg ± 50 mOsm / kg.
[0431] Surfactant Screening The effects of the surfactants polysorbate 20 and poloxamer 188 on the Vegf-Ang2 antibody were tested at different surfactant concentrations between 0.01% and 0.07%. In addition, formulations without surfactant were also tested.
[0432] Table 5 summarizes the test formulations for the surfactant screening.
[0433] Table 5 Formulation codes used for surfactant screening
[0434]
[0435]
[0436] Materials and Methods
[0437] The materials used in the preparation of the formulations and their primary packaging are provided in Tables 1 and 2.
[0438] The drug substance was buffer exchanged with 20 mM histidine-acetate (pH 5.3) diafiltration buffer by ultrafiltration-diafiltration using a Labscale TTF (Millipore) equipped with a semipermeable membrane with a molecular weight cut-off of 30 kD. Thus 250 mL of drug substance was filled into the Labscale system and buffer exchanged with 1700 mL of diafiltration buffer.
[0439] After buffer exchange, the drug substance was concentrated in a Labscale system to a protein concentration of approximately 170 mg / mL and a pH of approximately 5.5.
[0440] The concentrated drug substance was then diluted with the corresponding stock solutions of buffer and saline to a target protein concentration of 120 mg / mL to obtain the final drug solution as shown in Table 5.
[0441] Each drug solution was filtered through a 0.22 μm Sterivex GV (Millipore) filter and filled into clean and sterile 6 mL vials with a fill volume of 2.7 mL. The vials were stoppered and crimped.
[0442] Analytical methods
[0443] Protein concentration, pH, osmotic pressure, turbidity, viscosity, visible particles and SE-HPLC analysis detection methods are described in Example 1.
[0444] Stability Study Program
[0445] In the surfactant screening, the mechanical stress test conditions applied were: horizontal shaking at 2-8°C (200 rpm) for 1 week, horizontal shaking at 25°C (200 rpm) for 1 week, and 5 freeze-thaw cycles (-40°C / 5°C).
[0446] result
[0447] Table 6 summarizes the initial results of the surfactant screening samples. All formulations had a protein concentration of about 120 mg / mL and a pH of 5.5±0.1. The measured osmotic pressure was between 335 mOsm / kg and 350 mOsm / kg, which was slightly higher than the target value of 311 mOsm / kg. The selected formulation matrix (120 mg / mL Vegf-Ang2 with 20 mM histidine-acetate buffer at pH 5.5 and 25 mM sodium chloride and 180 mM sucrose) can obtain a low viscosity of about 15 mPas and a reduced turbidity (20 FTU).
[0448] Surfactant screening formulations were exposed to oscillation stress at 5°C and 25°C and freeze-thaw stress (five freeze-thaw cycles) and analyzed for visible particles and soluble aggregates (HMWS).
[0449] Table 7 summarizes the visible particle results at initial conditions and after physical stress. All formulation samples were free of particles at initial conditions. The surfactant-free formulation GRM0071-01 consistently exhibited many particles after exposure to different physical stress conditions. The addition of at least 0.01% polysorbate 20 prevented the formation of visible particles during exposure to the three physical stress methods.
[0450] Surprisingly, the addition of poloxamer was unable to prevent the formation of visible particles after 1 week of shaking at 5 °C, but it was able to protect the protein under shaking and freeze-thaw stress conditions at 25 °C.
[0451] Figure 4 The soluble aggregate content (HMWS) of the initial sample and the stressed sample is shown. The surfactant-free formulation GRM0071-01 (1) is sensitive to oscillation stress and exhibits an increase in aggregate content of up to 10% after 1 week of oscillation at 5°C and 25°C. The presence of 0.01% polysorbate 20 is not enough to completely prevent the increase in soluble aggregates after 1 week of oscillation at 25°C, because the aggregate content increases from 3% to 3.8%. Surprisingly, to prevent the increase in soluble aggregates after 1 week of oscillation at 25°C, it is necessary to use a polysorbate 20 content equal to or higher than 0.03%.
[0452] Table 6 Summary of protein concentration, pH, osmotic pressure, turbidity and viscosity of surfactant screening samples after production
[0453]
[0454]
[0455] Table 7 Summary of visible particle results for surfactant screening samples under initial conditions and after physical stress
[0456]
[0457] in conclusion
[0458] At least 0.03% polysorbate 20 was required to fully stabilize the anti-VEGF / ANG2 antibody at a concentration of 120 mg / mL under shaking and freeze-thaw stress conditions.
[0459] Under oscillatory stress conditions at 5°C, the surfactant poloxamer was unable to protect the bispecific anti-VEGF / ANG2 antibody at a concentration of 120 mg / mL.
[0460] The formulation matrix (comprising 20 mM histidine-acetate buffer (pH 5.5), 25 mM sodium chloride, and 180 mM sucrose) provided acceptable turbidity (approximately 20 FTU) and viscosity results (approximately 15 mPas) for the 120 mg / mL anti-VEGF / ANG2 antibody formulation.
[0461] Example 5: Excipient Screening I
[0462] set up
[0463] The scope of the excipient screening was used to select the final composition of the commercial formulation of the anti-VEGF / ANG2 antibody CrossMAb VEGFang2-0016 (fariximab).
[0464] Based on the results of the previous pH / buffer screening I and II and the surfactant screening, the selected formulation matrix consisted of 120 mg / mL Vegf-Ang2 antibody, 20 mM histidine acetate buffer system, 160 mM sucrose and 0.04% polysorbate 20. In this formulation matrix, the effects of pH (5.5 and 5.8), salt (25 mM sodium chloride and 8 mM calcium chloride) and methionine (0 mM and 7 mM) were tested. Based on the contribution of the buffer and salt concentrations, the ionic strength was adjusted to 40.
[0465] Table 8 summarizes the formulations for Excipient Screen I.
[0466] Table 8: Excipient Screening Part I Drug Product Code
[0467]
[0468] Materials and Methods
[0469] The materials used in the preparation of the formulations and their primary packaging are provided in Tables 1 and 2.
[0470] The drug substance was buffer exchanged with 20 mM histidine-acetate (pH 5.3) diafiltration buffer or 20 mM histidine-acetate (pH 5.6) by ultrafiltration-diafiltration using a Labscale TTF (Millipore) equipped with a semipermeable membrane with a molecular weight cut-off of 30 kD. Thus 410 mL of drug substance was filled into the Labscale system and buffer exchanged with 3000 mL of diafiltration buffer.
[0471] After buffer exchange, the drug substance was concentrated in a Labscale system to a protein concentration of approximately 165 mg / mL and a pH of approximately 5.5 or pH 5.8.
[0472] The concentrated drug substance was then diluted with the corresponding stock solutions of buffer and saline to a target protein concentration of 120 mg / mL to obtain the final drug solution as shown in Table 8.
[0473] Each drug solution was filtered through a 0.22 μm Sterivex GV (Millipore) filter and filled into clean and sterile 6 mL vials with a fill volume of 2.7 mL. The vials were stoppered and crimped.
[0474] Analytical methods
[0475] Protein concentration, pH, osmotic pressure, turbidity, viscosity, visible particles, SE-HPLC and IE-HPLC analytical detection methods are described in Example 1.
[0476] Stability Study Program
[0477] The formulations were stable for up to 20 weeks at 2-8°C and up to 13 weeks at 25°C. In addition, the samples were shaken horizontally for 1 week at 2-8°C (200 rpm), 1 week at 25°C (200 rpm), and subjected to 5 freeze-thaw cycles (-40°C / 5°C).
[0478] result
[0479] Table 9 summarizes the preliminary results of excipient screening I. The protein concentration of all formulations was between 125 mg / mL and 130 mg / mL. The measured pH values of formulations GRM0073-01 to GRM0073-04 with a target pH of 5.5 were about 5.6, while the measured pH values of formulations GRM0073-05 to GRM0073-08 with a target pH of 5.8 were about 5.9. The formulations containing 25 mM sodium chloride (GRM0073-01, GRM0073-02, GRM0073-05, and GRM0073-06) had higher osmotic pressure results (between 313 and 322 mOsm / kg) compared to the osmotic pressures (between 273 and 288 mOsm / kg) of the formulations containing 8 mM calcium chloride (GRM0073-03, GRM0073-04, GRM0073-07, and GRM0073-08).
[0480] Table 10 summarizes the results of visible particles under initial conditions and after physical stress and after storage at 5°C and 25°C for 13 weeks. After production and exposure to physical stress (shaking at 5°C or 25°C for 1 week, or after five freeze-thaw cycles), all formulations were free of particles. Surprisingly, all formulations containing 8mM calcium chloride showed visible particles after storage at 5°C and 25°C for 13 weeks, while all formulations containing 25mM sodium chloride were free of particles.
[0481] Figure 5 compares the turbidity and viscosity results for formulations containing 25 mM sodium chloride. Thus, the formulation with a pH of 5.5 exhibited lower turbidity (21 FTU vs. 25 FTU) and lower viscosity (17 mPas vs. 21 mPas).
[0482] Figure 6 and Figure 7 The increase in soluble aggregates (HMWS) during storage for 20 weeks at 5°C and 13 weeks at 25°C is shown. The pH 5.8 formulation showed a slight increase in soluble aggregates compared to the pH 5.5 formulation. Surprisingly, the addition of methionine reduced the formation of soluble aggregates and compensated for the effect of lower pH on aggregation.
[0483] Fig. 8 and Fig. 9 compare the changes of charged variants measured by IEC after storage at 5 ℃ for 20 weeks and 25 ℃ for 13 weeks, respectively.After storage at 5 ℃ for 13 weeks, the main peak area shown by all preparations decreased slightly by about 1%.Accompanied by an increase of about 0.2% in acidic variants, and an increase of about 1% in basic peak area.Different pH or the presence of methionine did not cause any obvious difference.Although the main peak decreased much more (about 18%) after storage at 25 ℃ for 13 weeks, pH and methionine did not cause obvious differences.During storage at 25 ℃, the decline of the main peak was mainly caused by the increase of acidic variants.
[0484] Table 9 Summary of protein concentration, pH and osmotic pressure results of excipient screening I samples after production
[0485]
[0486] Table 10 Summary of visible particle results for initial and stressed excipient screening I samples
[0487]
[0488] in conclusion
[0489] Although the presence of calcium chloride resulted in lower viscosity and turbidity levels than formulations containing sodium chloride (see Examples 2 and 3), it surprisingly also caused the formation of visible particles. <790> The requirement of "substantially free of visible particles" is that for intravitreal injections, the formation of visible particles is unacceptable. Therefore, compared with the use of calcium chloride, it is preferred to add sodium chloride as an ionic strength modifier to reduce viscosity.
[0490] In addition, the pH 5.5 formulation showed lower turbidity and lower viscosity compared to the pH 5.8 formulation. However, the pH 5.8 formulation showed slightly less soluble aggregate formation compared to the pH 5.5 formulation, but the addition of 7 mM methionine compensated for this effect. Therefore, the addition of methionine reduced the formation of soluble aggregates at pH 5.5 while still achieving lower viscosity and turbidity levels.
[0491] The difference in pH (pH 5.5 vs. 5.8) or the presence or absence of methionine had no effect on the formation of charged variants.
[0492] In summary, formulations containing 25 mM sodium chloride (instead of 8 mM calcium chloride) and 20 mM histidine-acetate buffer (pH 5.5) with 7 mM methionine, 160 mM sucrose, and 0.04% polysorbate 20 can provide particle-free formulations with low turbidity and low viscosity, with improved stability.
[0493] Example 6: Excipient Screening II
[0494] set up
[0495] In the second part of the excipient screen, stability was further characterized with prefilled syringes and a protein concentration of 30 mg / mL.
[0496] Excipient Screening I resulted in a preferred formulation consisting of 120 mg / mL anti-VEGF / ANG2 antibody CrossMAb VEGFang2-0016 (fariximab), 20 mM histidine-acetate (pH 5.5), 25 mM sodium chloride, 160 mM sucrose, 7 mM methionine and 0.04% polysorbate 20, which was filled into glass vials (corresponding to formulation GRM0073-02).
[0497] The formulation was also filled into prefilled syringes (GRM0076-02). In addition, the stability of the formulation matrix filled into prefilled syringes (GRM0077-02) or glass vials (GRM0077-06) was tested at a protein concentration of 30 mg / mL.
[0498] For comparison, the stability of the reference formulations filled into glass vials was tested at 30 mg / mL (GRM0077-09) and 120 mg / mL (GRM0076-05).
[0499] Table 11 summarizes the formulations for Excipient Screen II.
[0500] Table 11: Excipient Screening Part II Formulation Code
[0501]
[0502] Materials and Methods
[0503] The materials used in the preparation of the formulations and their primary packaging are provided in Tables 1 and 2.
[0504] The drug substance was buffer exchanged by ultrafiltration-diafiltration using a Labscale TTF (Millipore) equipped with a semipermeable membrane with a molecular weight cut-off of 30 kD.
[0505] To prepare the anti-VEGF / ANG2 antibody CrossMAb VEGFang2-0016 (fariximab) in 20 mM histidine-acetate buffer (pH 5.5), approximately 340 mL of drug substance was filled into the Labscale system and buffer exchanged with 2400 mL of 20 mM histidine-acetate (pH 5.2) diafiltration buffer.
[0506] The anti-VEGF / ANG2 antibody CrossMAb VEGFang2-0016 (Fariximab) was prepared in 20 mM histidine-HCl buffer (pH 6.0) using approximately 200 mL of bulk drug substance, which was filled into a Labscale system and buffer exchanged with 1400 mL of 20 mM histidine-HCl (pH 5.85) diafiltration buffer.
[0507] After buffer exchange, the corresponding drug substance was concentrated in a Labscale system to a protein concentration of about 165 mg / mL and a pH of about 5.5 or pH 6.0.
[0508] The concentrated drug substance was then diluted with the corresponding stock solutions of buffer and saline to a target protein concentration of 30 mg / mL to 120 mg / mL to obtain the final drug solution as shown in Table 8.
[0509] Each drug solution was filtered through a 0.22 μm Sterivex GV (Millipore) filter and filled into clean and sterile 6 mL vials (filling volume was 2.7 mL), or filled into clean and sterile 1 mL prefilled syringes (filling volume was 1 mL). The vials were stoppered and crimped, while the syringes were closed with a plunger stopper.
[0510] Analytical methods
[0511] Protein concentration, pH, osmotic pressure, turbidity, viscosity, visible particles and SE-HPLC analysis detection methods are described in Example 1.
[0512] Stability Study Program
[0513] The formulations were stable for up to 13 weeks at 2-8°C and 24°C. In addition, the samples were shaken horizontally for 1 week at 2-8°C (200 rpm), 1 week at 25°C (200 rpm), and subjected to 5 freeze-thaw cycles (-40°C / 5°C).
[0514] result
[0515] Table 12 summarizes the initial results of excipient screening II. The target protein concentration of 120 mg / mL for GRM0076-02 (optimized formulation in PFS) and GRM0076-05 (reference formulation) matches the measured value of 119 mg / mL or 123 mg / mL, respectively. GRM0077-02 (optimized formulation in PFS), GRM0077-06 (reference formulation in vial) and GRM0076-05 (reference formulation) with a target protein concentration of 30 mg / mL were prepared. The actual protein concentration range is between 30 mg / mL and 31 mg / mL.
[0516] The pH of all formulations was close to the target pH, with a maximum deviation of only 0.1 pH unit.
[0517] The osmolality of the formulation at 120 mg / mL was slightly higher (between 310 and 320 mOsm / kg), while the osmolality of the 30 mg / mL formulation was between 278 and 394 mOsm / kg.
[0518] Table 13 summarizes the results of visible particles under initial conditions and after physical stress and after storage at 5°C and 25°C for 13 weeks. After production and exposure to physical stress (shaking at 5°C or 25°C for 1 week, or after five freeze-thaw cycles), all formulations were free of particles. Surprisingly, the reference formulation showed many particles after storage at 5°C and 25°C for 13 weeks. All other formulations were free of particles.
[0519] Figure 10 compares the turbidity and viscosity results of the optimized formulation and the reference formulation at a protein concentration of 120 mg / mL. The optimized formulation exhibits significantly lower turbidity (about 23 FTU), while the turbidity of the clinically used formulation exceeds 45 FTU. Interestingly, the viscosity of both formulations is less than 14 mPas.
[0520] Figure 11 shows the turbidity and viscosity of 30 mg / mL formulations. Here, the turbidity difference between formulations GRM0072-02 and GRM0077-09 is small, but the optimized formulation still shows lower turbidity. Compared with the 120 mg / mL formulation, the viscosity of the two 30 mg / mL formulations is very low and is less than 2 mPas.
[0521] Fig.12 and Fig.13 The increase in HMW content after storage at 5°C and 25°C for 13 weeks is shown. The increase in HMW content of the optimized formulations of 120 mg / mL and 30 mg / mL is less than that of the reference formulation. After storage at 25°C for 13 weeks, the stabilization effect is most obvious, where the HMW in the optimized formulation GRM0076-02 only increased to 2.4%, while the formulation GRM0076-05 increased to as high as 2.9%. The same trend was observed in the 30 mg / mL formulation, with a lower increase in the optimized formulation (1.0%), while the reference formulation increased to 1.3%.
[0522] Figure 14 compares the changes in charged variants measured by ICE after storage at 5°C and 25°C for 13 weeks. After storage at 5°C for 13 weeks, the main peak area of all preparations decreased slightly (about 1%). And there was a corresponding increase in the alkaline peak area, while the acidic peak area remained constant. Although the main peak decreased much more (about 10%) after storage at 25°C for 13 weeks, no significant differences were found between the preparations. During storage at 25°C, the decline in the main peak was mainly due to the increase in acidic variants (about 8%) and a slight increase in alkaline variants (1-2%). After storage at 25°C for 13 weeks, the increase in alkaline variants in the reference preparation (prepared to pH 6.0) was slightly lower (about 1%) than the optimized preparation (increased by about 2%). Lower protein concentrations and primary containers have no effect on charged variants.
[0523] Table 12 Summary of protein concentration, pH and osmotic pressure results of excipient screening II samples after production
[0524]
[0525] Table 13 Summary of Visible Particle Results for Initial and Stressed Excipient Screening II Samples
[0526]
[0527]
[0528] in conclusion
[0529] The results of excipient screening II confirmed that the optimized formulation was superior to the reference formulation. The turbidity of the optimized formulation of 120 mg / mL was reduced from more than 45 FTU to less than 25 FTU, while maintaining a viscosity of less than 15 mPas. Low viscosity is essential for achieving a commercial-scale production process (concentrated by ultrafiltration) and ensuring easy and convenient intravitreal injection (injection force less than 20N, especially less than 15N). It has been demonstrated that an optimized formulation with a viscosity of less than 15 mPas can be injected with an injection force of less than 5N in an injection time of 5s through a 30G injection needle.
[0530] Furthermore, the optimized formulation at 30 mg / mL remained free of particles, whereas the reference formulation exhibited visible particles after 13 weeks of storage at 5°C and 25°C. In addition, the increase in HMW species was lower in the optimized formulation.
[0531] Improved stability of the optimized formulation was observed at protein concentrations of 30 mg / mL and 120 mg / mL and in vials and prefilled syringes.
[0532] In summary, optimized formulations with protein concentrations between 30 mg / mL and 120 mg / mL (containing histidine-acetate buffer at pH 5.5, 25 mM sodium chloride, 7 mM methionine, 160 mM sucrose, and 0.04% polysorbate 20) provide particle-free formulations with low turbidity and low viscosity, and have improved stability in vials and prefilled syringes.
[0533] Example 7: Safety of Methionine in Ocular Indications (in Formulations for Intravitreal Administration)
[0534] Overview of nonclinical toxicity studies of L-methionine
[0535] A toxicity study was performed in cynomolgus monkeys in which methionine (10 mM) was a component of the vehicle and the formulated test article CrossMAb VEGFang2-0016 (Fariximab). In this study, a total of 12 animals (6 males / 6 females) were treated intravitreally with a dose of 50 μL per eye, twice with an interval of 14 days between the two treatments. The left eye was treated with the vehicle (containing 10 mM methionine) and the right eye was treated with the formulated test article CrossMAb VEGFang2-0016 (Fariximab) (also containing 10 mM methionine). In this study, no ocular effects of methionine were seen in cynomolgus monkeys.
[0536] Three studies were conducted (in cynomolgus monkeys and New Zealand white rabbits) in which methionine (5-25 mM) was a component of the vehicle and was administered intravitreally (dose was also 50 μL per eye) up to six times with 14 days between each administration. In these studies, no ocular effects of methionine were observed in any animal treated with methionine-containing vehicle.
[0537] A summary of the nonclinical toxicity studies is provided in Table 14.
[0538] Table 14 Summary of nonclinical toxicity studies involving methionine (intravitreal administration)
[0539]
[0540] Abbreviations: NAT = N-acetyltryptophan; NZW = New Zealand White.
[0541] Example 8: Stability
[0542] A batch of drug product (120 mg / mL Vegf / Ang2 antibody (Faliximab) in 20 mM L-histidine-acetate (pH 5.5), 160 mM sucrose, 25 mM sodium chloride, 7 mM L-methionine, 0.04% polysorbate 20) was filtered through a 0.22 μm sterile filter and filled into clean and sterile 2 mL vials (fill volume 0.24 mL).
[0543] The resulting formulation had a pH of 5.6, an osmotic pressure of 320 mOsm / kg and a protein concentration of 120 mg / mL.
[0544] Table 15 shows the stability data for drug product batch GLI0219-01 during storage at 5°C. Table 16 shows the stability during storage at 25°C.
[0545] Table 15 Stability data of Vegf-Ang2 antibody (Fariximab) drug batches during storage at 5°C
[0546]
[0547] Table 16: Stability data of Vegf-Ang2 antibody (Fariximab) drug batches during storage at 25°C
[0548]
[0549] abbreviation
[0550] abbreviation describe His / Ace Histidine-acetate buffer His-HCl Histidine-HCl buffer SE-HPLC Size Exclusion High Performance Liquid Chromatography IE-HPLC Ion exchange HPLC FTU Formazine Turbidity Units HMW High molecular weight substances mPas Millipascal second LMW Low molecular weight substances mg / mL mg / mL < / vegf>
Claims
1. A liquid pharmaceutical preparation comprising: 120 mg / mL ± 18 mg / mL of a bispecific anti-VEGF / ANG2 antibody comprising a heavy chain constant region of the human IgG1 subclass, 15mM to 35mM sodium chloride, 15mM to 25mM histidine acetate buffer, Its pH value is 5.5 ± 0.5; The bispecific anti-VEGF / ANG2 antibody is faricimab, wherein the formulation has a viscosity of 20 mPas or less, which is measured on a rheometer at a taper of 25 mm-0.5°, 1000 s -1 and a temperature of 20° C., and the formulation has a turbidity of 30 FTU or less, as measured on a turbidimeter.
2. The liquid pharmaceutical formulation according to claim 1, which is for intravitreal administration.
3. The liquid pharmaceutical formulation of claim 1, wherein the formulation is substantially free of visible particles.
4. The liquid pharmaceutical preparation according to any one of claims 1 to 3, wherein the preparation further comprises 1 mM to 20 mM of at least one stabilizer.
5. The liquid pharmaceutical preparation according to any one of claims 1 to 3, wherein the preparation further comprises 7.0 mM ± 2.0 mM methionine.
6. The liquid pharmaceutical preparation according to any one of claims 1 to 3, wherein the preparation further comprises 0.01% (w / v) to 0.07% (w / v) surfactant.
7. The liquid pharmaceutical preparation according to any one of claims 1 to 3, wherein the preparation further comprises 0.03% (w / v) to 0.07% (w / v) polysorbate 20.
8. The liquid pharmaceutical preparation according to any one of claims 1 to 3, wherein the preparation further comprises 50mM to 250mM tonicity agent.
9. The liquid pharmaceutical formulation according to any one of claims 1 to 3, wherein the formulation further comprises 160 mM ± 24 mM sucrose.
10. The liquid pharmaceutical formulation according to any one of claims 1 to 3, wherein the formulation has an ionic strength between 20 and 50, which is calculated by the following formula: where I is the dimensionless ionic strength; z is the charge of ion I, and b i is its weight molar concentration, b θ Corresponds to 1 mol / kg.
11. The liquid pharmaceutical formulation according to any one of claims 1 to 3, wherein the formulation is a stable formulation.
12. The liquid pharmaceutical formulation according to any one of claims 1 to 3, wherein the content of high molecular weight substances (HMW) of the bispecific antibody in the pharmaceutical formulation is less than 10% after storage of the pharmaceutical formulation at 25°C for 8 weeks or after storage of the pharmaceutical formulation at 25°C for 52 weeks.
13. The liquid pharmaceutical formulation according to any one of claims 1 to 3, wherein the osmotic pressure of the formulation is 300 mOsm / kg ± 100 mOsm / kg, as measured on an osmometer according to the freezing point depression principle.
14. Use of the liquid pharmaceutical formulation according to any one of claims 1 to 3 in the preparation of a medicament for treating ocular vascular diseases.
15. The use according to claim 14, wherein the ocular vascular disease is selected from the group consisting of diabetic retinopathy (DR), diabetic macular edema (DME), retinal vein occlusion (RVO), central retinal vein occlusion (CRVO), macular degeneration, wet age-related macular degeneration (wet AMD), retinopathy of prematurity (ROP), neovascular glaucoma, retinitis pigmentosa (RP), retinal angiomatous proliferation, macular telangiectasia, ischemic retinopathy, iris neovascularization, intraocular neovascularization, corneal neovascularization, retinal neovascularization, choroidal neovascularization and retinal degeneration, in particular selected from the group consisting of diabetic retinopathy (DR), diabetic macular edema (DME), retinal vein occlusion (RVO), central retinal vein occlusion (CRVO), wet age-related macular degeneration (wet AMD).
16. A method for preparing the pharmaceutical preparation according to any one of claims 1 to 13, the method comprising the following steps: The bispecific antibody bulk solution is a) buffer exchanged with a diafiltration buffer by ultrafiltration and diafiltration, or b) buffer exchanged by dialysis using a dialysis buffer comprising histidine-acetate buffer, or histidine-acetate buffer and sodium chloride, or histidine-acetate buffer, sodium chloride and methionine, or histidine-acetate buffer, sodium chloride, methionine and sucrose The bulk solution of the buffer exchange was concentrated by ultrafiltration The final composition of the pharmaceutical preparation is adjusted by adding stock solutions of the corresponding excipients or by appropriate adjustment of the buffer, and the liquid pharmaceutical preparation is homogenized by mixing.
17. A vial comprising the pharmaceutical formulation according to any one of claims 1 to 13.
18. A prefilled syringe comprising the pharmaceutical formulation according to any one of claims 1 to 13.
19. A lyophilized form of the liquid pharmaceutical formulation according to any one of claims 1 to 13.
